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Systemic Lupus Erythematosus (SLE) is a multisystem autoimmune disease 
characterised by the formation of antinuclear antibodies.1  SLE is the most common 
autoimmune disease, with an estimation of incidence ranging from 2.0 to 7.6 per 
100,000 and prevalence of 20 to 50 per 100,000.2-4  The proportion of these patients 
who present in childhood has been estimated at 15-20%.1  The disease appears to be 
more common in Europe, Asia and the Americas than in Africa, but much higher in 
patients of African ancestry living in the United States, United Kingdom or the 
Caribbean Islands.5-7  The prevalence of SLE in adult Black South Africans has been 
estimated to be 12.2/100,000, though there are no accurate figures available for 
children in South Africa.8,9 Childhood-onset SLE in South Africa has not been well 
documented.  Faller et al reported on a cohort of 36 patients from the Gauteng region 
of South Africa and suggested that this disease is being increasingly recognized in 
Black South African children as the socioeconomic and political landscape has 
shifted.10  There is a perception that SLE is more common in the Western Cape of 
South Africa than in other parts of the country and that the disease has a higher 
morbidity and mortality than is documented in other countries.  The patient profile, 
disease characteristics, morbidity and complications have not been described in the 
Western Cape, which has a different genetic profile to other parts of South Africa. 
 
Aims 
We aim to document the disease characteristics, disease activity, morbidity and 
treatment practices in our cohort of patients with childhood-onset SLE from Cape 
Town, South Africa.  
 
Methods 
A retrospective folder review of all patients with Paediatric SLE seen at Red Cross 
War Memorial Children’s Hospital and Groote Schuur Hospital will be done. 
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Clinical and demographic data will be retrospectively collected as per the data 
collection sheet in appendix 1.  The diagnostic criteria using the American College of 
Rheumatology (ACR) criteria will be used to confirm the diagnosis of SLE (see 
appendix 2).  In addition the System Lupus International Collaborating 
Clinics/American College of Rheumatology Damage Index (SLICC/ACR DI) for SLE 
will be calculated at onset, 1 year disease activity, 5 year disease activity and at the last 
visit (see appendix 3). 
Analysis of disease characteristics will be done for various subgroups and predictors 
for increasing damage or mortality will be investigated. 
Ethical Considerations 
The study will be conducted according to the ethical guidelines and principles of the 
international Declaration of Helsinki, South African Guidelines for Good Clinical 
Practice and the Medical Research Council (MRC) Ethical Guidelines for Research. 
Benefits to Individual Patients.  As this is a retrospective study there will be no direct 
benefit to patients in this study. 
Benefits to the Community.  By doing this study we hope to gain insight into SLE in 
South African children.  This will have a beneficial spin off for the community as a 
whole. 
Risks to Patients.  There are no risk factors to the patient. 
Investigations on Study Patients.  No additional investigations will be done on study 
patients.  Tests done at the time of treatment at the institution may be presented in the 
study. 
Confidentiality.  Patients with SLE will be identified from the hospital database.  Their 
files will be drawn and the required information will be recorded in an electronic 
database under a study number or letter.  A separate file will be kept linking the study 
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number to the patient.  This information will be kept on a computer that needs a code 
to gain access to it.  Only the principal investigator will have access to this computer. 
 
Children as Research Subjects (why not adults or experimental animals).  Data from 
adult studies cannot be applied to paediatric practice due to differences in the clinical 
course of the disease.  Consequently data needs to be obtained from an appropriate 
sample of infants and children. 
 
Consent.  To obtain consent from parents in this population will be difficult and 
probably not possible in most cases.  We feel that there is important information in this 
study and in the interest of benefit to the community at large would like to ask for a 
waiver of consent. 
 
Budget.  There are no costs associated with this study. 
 
Conclusion 
The findings will enable us to describe the characteristics, morbidity and mortality of 
the disease in our disease population and to critically consider our treatment practices, 
which may lead to further study or changes in our clinical practice to better serve our 
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Systemic Lupus Erythematosus (SLE) is a multisystem, inflammatory, autoimmune 
disease that is characterised by the formation of antinuclear antibodies.1  It is the most 
common autoimmune disease with an estimated incidence ranging from 2.0 to 7.6 per 
100,000 and prevalence of 20 to 150 per 100,000.2-5  Although more commonly 
presenting in adulthood, it is thought that childhood onset SLE is becoming 
increasingly recognized.6  Approximately 15-20% of SLE occurs before the age of 19 
years.1,7,8 
 
There is a wide variability in disease presentation and course.  It is known that SLE 
presents differently, not only in respect to age, but also depending on the ethnic 
background and gender of the patient.3,9-11  The disease appears to be more common in 
Europe, Asia and the Americas than in Africa, but much higher in patients of African 
ancestry living in the United States, United Kingdom (UK) or the Caribbean Islands.12-
14  There is a female preponderance, but this is also known to vary according to 
age.3,8,15,16  The prevalence of SLE in adult Black South Africans has been estimated to 
be 12.2/100,000, although there are no accurate figures available for children in 
Southern Africa.17,18 
 
The diagnosis of SLE is a clinical and laboratory diagnosis based on the American 
College of Rheumatology (ACR) Classification Criteria for SLE (see Appendix 2).  In 
1982, the ACR established eleven criteria for the diagnosis of SLE, which were 
revised in 1997.19,20  Four of the eleven criteria are required to be present for the 
diagnosis of SLE to be confirmed.  This criteria, however, was established mainly for 
use in scientific research, so some people, especially those with lupus nephritis or 
antiphsopholipid syndrome, may have SLE without four of the criteria.  SLE 
frequently presents with features other than those in the ACR criteria, for example 
fever, lymphadenopathy, photosensitivity and alopecia. 
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Childhood-onset SLE has a more aggressive course than adult-onset disease.21-23  The 
disease in children more often has major organ involvement as a presenting 
manifestation, with renal, central nervous system and haematological problems 
predominating.  Children with SLE appear to be more susceptible than adults to 
nephritis, and the nephritis itself seems to be more severe in nature.8  Renal disease 
contributes significantly to the long-term morbidity and mortality in children with SLE 
and is thought to be one of the main poor prognostic factors in childhood-onset SLE.  
A poor outcome has been noted particularly with diffuse proliferative nephritis.24-26  
Renal disease secondary to SLE is reported to be present in 29-80% of paediatric SLE 
cases.27  Reporting bias may be the cause of this wide variation in renal disease with 
many studies being based in Nephrology clinics.  A more accurate figure may be of 
approximately 50% in a combined Nephrology/Rheumatology clinic.28 
 
The severity of the renal disease was highlighted by an early study on childhood-onset 
SLE from the UK in which 47.6% of patients had renal disease during the course of 
their follow-up.  In these patients, none of the children without renal disease died, 
while in the patients with nephritis, the five- and ten-year survival was 59.5% and 
47.6% respectively.25  However, the association of renal disease and a poorer outcome 
has been refuted, even in those with advanced renal disease at presentation.29 
 
Outcome scoring for SLE is controversial.  Deciding whether a child who has been 
diagnosed with SLE has a greater or lesser degree of disease activity and determining 
how to avoid disease damage are essential for patient management. 
 
It is not possible to use one individual clinical sign or laboratory value to measure the 
progression of the disease.  To help with this, indices of disease activity and damage 
have been developed for use in adults with SLE.30-34  These same indices are being 
used in children.  One such tool, the Systemic Lupus Erythematosus Disease Activity 
Index (SLEDAI) has been validated for use in patients with childhood-onset SLE.35,36 
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The Systemic Lupus International Collaborative Clinics/American College of 
Rheumatology Damage Index (SLICC/ACR DI) is the only currently available 
instrument for measuring disease damage in SLE (see Appendix 3).31  It was 
recognised that damage from inflammation cannot be clearly distinguished from 
damage secondary to medication side effects or other co-morbid conditions; therefore 
both disease specific and non-disease specific damage are included in the SLICC/ACR 
DI.  It quantifies non-reversible cumulative damage, which has occurred since the 
onset of the disease.  It records damage in twelve organs/systems and has a score range 
from 0 to 47. Damage is considered non-reversible if any given item was present for at 
least six months continuously.  It is a useful tool for measuring disease damage in 
adults and children with SLE.37-41 
 
In SLE, there is a bimodal pattern of mortality, either from initial disease activity or 
from complications relating to either the disease itself or from therapies used in the 
treatment of the disease.42  Renal disease has been shown to be one of the major poor 
prognostic factors, therefore it is important to identify those at high risk for renal 
failure and tailor therapy regimens appropriately.24-26  Recent improvements in early 
diagnosis, recognition of milder forms of the disease and improved management 
strategies are thought to account for the improvement in mortality that has been seen in 
childhood-onset SLE.  In 1981, the five-year survival rate for childhood-onset SLE 













GW Spittal – Characteristics of Childhood-onset SLE in Cape Town, South Africa. 
University of Cape Town February 2014 15
SLE in Sub-Saharan Africa 
Childhood-onset SLE in Sub-Saharan Africa has been poorly reported on.  It was first 
described in South Africa by Rovers and Coovadia in 1981 in a case report of three 
children of Indian descent in Durban.45  In 1986 Ransome and Thomson reported on 
six cases, none in Black African children, from the Gauteng region of South Africa.  
Renal disease was considered above the other systems as a major influencing system in 
the morbidity and mortality in childhood-onset SLE and they reported that of the six 
patients, one patient progressed to end stage renal disease (ESRD) while two had mild 
renal impairment.  Once again, this may just reflect the fact that the clinicians involved 
were nephrologists.46 
The first description of childhood-onset SLE in a Black South African child was in 
1991.  She was a ten year old girl from Durban, who presented with what was 
described as a fairly typical and full blown picture of SLE.  Her main presenting 
features were renal involvement, haemolytic anaemia and positivity for antinuclear 
antibodies.47 
A further study was published in 1994 reporting on the outcome of childhood-onset 
SLE in Durban.  Initially there was a 100% mortality of patients with childhood-onset 
SLE, but this was improved after changing the management practice in these patients.  
They concluded that with the judicious use of a few drugs, together with regular and 
meticulous follow-up, the prognosis of childhood-onset SLE can be greatly improved, 
even in third world countries.48 
In 2005, a cohort of 36 patients was reported on in a retrospective analysis from 
Gauteng, with the main objective of documenting the clinical features and 
demographics of children with SLE.  They concluded that SLE is being increasingly 
recognized in Black South African children.  South African children with SLE present 
in diverse ways, and the diagnosis is being missed early, therefore patients are 
presenting late with severe disease.49
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In 2007, Olowu published two studies, looking at a small number of Black African 
children in Nigeria.  The same eleven children were reported on, firstly describing 
their initial clinicolaboratory manifestations and short term outcome.  They reported 
both severe renal and extrarenal comorbidities, as well as a high mortality rate in their 
small cohort.  This was thought to be due to a high frequency of delayed and mis-
diagnoses.  All eleven of these patients had renal disease associated with their SLE, 
and the second study reported on the renal manifestations and outcomes of these 
patients.  There was a significant association of acute renal failure and tubular 
dysfunction in this series.  This deranged tubular function may be a marker of severe 
nephritis warranting early confirmatory renal biopsy and aggressive interventional 
treatment.50,51  
 
In the Western Cape of South Africa there is a large spectrum of ethnicity in the 
patient population.  The patient profile, disease characteristics, morbidity and 
complications have not been described in the Western Cape, which has a different 
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Why is Cape Town Different? 
 
South Africa, and Cape Town in particular, has a multi-ethnic population.  Genetic 
studies suggest this group has the highest levels of mixed ancestry in the world, giving 
the Western Cape of South Africa a unique population mix.52 
 
In South Africa, ‘Coloured’ people are an ethnic group of mixed race people who 
possess some sub-Saharan ancestry.  The maternal contribution to the Coloured 
population has been shown to come mostly from the Khoisan population, but it is a 
mixed race possessing ancestry from Europe, Asia and other southern African 
countries.53,54 
 
The total number of children under the age of eighteen years old living in South Africa 
is estimated at about 18,771,000, and it is estimated that around 10% (1,789,000) of 
these are living in the Western Cape Province, where Cape Town is the main city.  
There is an almost equal sex incidence (51% males:49% females).55 
 
The total population of Cape Town is around 3.5million (B+C), with about 45% of the 
population being under the age of eighteen years.55-57  The age cut-off for use of 
Paediatric services in the Western Cape is less than fifteen years old and in 2007, 
children from 0-to-14 old years made up around 25.8% of the population of Cape 
Town.56 
 
In the whole of South Africa, there are many more Black African children compared to 
the other racial backgrounds, with around 85% of the total number of children under 
the age of eighteen years old being Black African.  Overall, 8% are Coloured, 5% are 
Caucasian and 2% are Indian.55  This is where Cape Town itself differs from the rest of 
South Africa.  Approximately 35% of the population is Black African, with Coloured 
people predominating (44%).  There is also a much larger proportion of people of 
Caucasian descent than in other areas of South Africa (19.3%).56  
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Objectives of this literature review 
 
The main objective of this literature review is to try to define the pattern of disease 
expression in patients with childhood-onset SLE throughout the world, looking 
specifically at presenting features, disease course, morbidity and mortality.  We 
wanted to look for any major differences in different racial backgrounds to see if this 
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Methodology 
The literature search was performed in PUBMED (www.ncbi.nlm.nih.gov/pubmed/), 
using the following search strings: 
 
 SEARCH 1 - SLE + Africa = (SLE[All Fields] AND (“Africa”[MeSH Terms] 
OR “africa”[All fields]));  
 
 SEARCH 2 - SLE + characteristics = (SLE[All fields] AND characteristics[All 
fields]); 
  
 SEARCH 3 - SLE + clinical features = (SLE[All fields] AND “clinical 
features”[All fields]); 
  
 SEARCH 4 - SLE + diagnostic features = (SLE[All fields] AND 
(“diagnosis”[MeSH Terms] OR “diagnosis”[All fields] OR “diagnostic”[All 
fields] AND “features”[All fields])).  
 
Results were limited to humans, children less than 18 years old and English language 
articles.  There was some overlap between the searches above, but all article abstracts 
were obtained and reviewed. 
 
Abstracts dealing with adults only or with the management of SLE only were 
excluded.  All abstracts including patients with neonatal SLE were excluded.  
Abstracts dealing with drug-induced lupus, mixed connective disease and other 
rheumatological disease, in particular Juvenile Idiopathic Arthritis, were excluded.   
 
It is well known that SLE is a multisystem disease that can cause severe abnormal 
outcomes in numerous body systems.  According to the ACR diagnostic criteria, as 
well as outcome score indexes, many systems are commonly affected in SLE.20,31,35  
Lupus nephritis and neuropsychiatric lupus, in particular, are popular topics in studies.  
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As this study was an overview of all presenting features, any articles that dealt 
exclusively with these specific systems were excluded.   
 
Laboratory-based articles that dealt only with biochemical, haematological or 
immunological results but did not contain enough clinical information were excluded.  
Articles from the same institutions reporting on a patient cohort that was already 
included in a larger or more comprehensive study were excluded. 
 
The remaining articles were retrieved and reviewed in full text, and the same criteria 
applied. Reference lists of all full text articles reviewed were screened for other 
possible articles.  Systematic reviews were not included in the final analysis, but the 
reference lists were screened for other possible articles.  Epub before print reports were 
reviewed and included where relevant.   
 
The primary aims of the studies varied and were not part of the main inclusion criteria.  
To be included, all articles had to fulfill the following basic criteria: 
 
 Age cut-offs for ‘children’ clearly defined;  
 Patient cohort of more than 30 patients; 
 Diagnosis of SLE made on ACR criteria, or if at least four of the criteria was 
not met, an adequate explanation was given e.g. lupus nephritis on biopsy; 
 Basic demographic details given including age and sex – age at either onset of 
symptoms or diagnosis was required; 
 Main clinical features at the time of presentation or diagnosis given. 
 
Retrospective and prospective studies were included, but an accurate description of 
study methodology was required to allow definition of the study type. 
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Articles involving both adults and children were included if the information given on 
the childhood-onset cohort met the above criteria and was described separately.  The 
adult data from these studies was excluded from the analysis.  
Outcomes studied in the articles included SLICC/ACR DI scores, mortality and 
specific renal outcomes.  Renal outcomes varied widely between articles, but were 
included if mortality, number progressing to renal failure or chronic kidney disease, or 
the number requiring dialysis or a renal transplantation were documented.  
It was not possible to do a meta-analysis using the available literature due to different 
methodology and reporting in the studies. 
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Results 
The search was carried out on the 1st of February 2011.   





















Search 4 – SLE + diagnostic features 374 results 
Search 3 – SLE + clinical features 239 results 
Search 2 – SLE + characteristics 217 results Search 1 – SLE + Africa 53 results 
Abstracts reviewed and exclusion criteria applied Some overlap between searches 
16 full text articles reviewed 29 full text articles reviewed 25 full text articles reviewed 45 full text articles reviewed 
Exclusion criteria applied to all full text articles 
Basic inclusion criteria not met Basic inclusion criteria met 
94 articles excluded or not meeting basic inclusion criteria 21 articles included in the final analysis 
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In summary, the 4 search strings yielded 883 articles.  One hundred and fifteen of 
these articles were reviewed in full text and 21 studies were included in the final 
analysis. 
 
There were sixteen retrospective studies, two retro- and prospective studies and three 
prospective studies. 
 
The studies were from many different parts of the world, most commonly from the 
Middle East, including Egypt in North Africa (n=6) and Europe (n=5).  South America 
(n=4), North America (n=3), the Far East (n=2) and Sub-Saharan Africa and the Indian 
Subcontinent (n=1) made up the rest of the studies analysed.  One of the studies was a 
direct comparison of African American patients in the United States of America (USA) 
and Latin American patients in Colombia, South America. 
 
The studies were published from 1981 to 2009, and included data from 1956 to 2006. 
 
All of the studies were conducted in tertiary referral units, with one primarily from a 
Nephrology unit and eight primarily from Rheumatology/Immunology units.  Three 
studies were from primarily General Paediatric units with three studies also from 
mixed units incorporating Nephrology, Rheumatology and Haematology departments.  
There were six multicentre studies. 
 
The age cut offs for the different studies were as follows: 
 
 <14years = 3 studies; 
 <15years = 1 study; 
 <16years = 7 studies; 
 <17years = 5 studies; 
 <18years = 5 studies. 
GW Spittal – Characteristics of Childhood-onset SLE in Cape Town, South Africa.  
University of Cape Town February 2014  24
Many of the studies had multiple objectives.  The main objectives of the studies 
included in the analysis were: 
 
 Describing demographic, clinical and laboratory/immunological features at 
presentation, including major organ involvement, and defining pattern of 
disease expression = 20 studies;  
 Morbidity, mortality and survival rate = 2 studies; 
 Comparing clinical features in different racial groups = 1 study; 
 Clinical and laboratory features at presentation and their association with 
outcome OR prognostic factors at presentation = 5 studies. 
 
A total of 1996 patients were analysed, 1697 in retrospective or retro- and prospective 
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Overview of results 
In all the studies analysed, 371 patients were males, giving a male to female ratio of 
1:5.4.   
 
The most reported on clinical features at presentation were renal involvement 
(n=1996), anti double-stranded DNA (antidsDNA) antibodies (n=1901), antinuclear 
antibody (ANA) status (n=1840), central nervous system (CNS) involvement (n=1693) 
and thrombocytopenia (n=1610). 
 
The commonest clinical presenting features were arthritis in 64.5% (894/1385) and 
cutaneous features in 62.9% (544/881).  Malar rash was present in 58.7% of patients 
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The commonest laboratory findings were a positive ANA in 96.1% of patients 
(1768/1840), a raised erythrocyte sedimentation rate (ESR) in 91.5% of patients 
(505/552) and hypocomplementaemia.  Studies reported on different complement 
levels, with 71.8% reporting on a low C3/C4 level (163/227), while 79% reported a 
low C3 (561/710) and 70.3% reported a low C4 level (499/710). 
 
 
Figure 2.  Laboratory findings. 
 
Of all the reporting done, the highest number of patients had positive ANA 
(1768/1840) and antidsDNA antibodies (1391/1901), malar rash (895/1525), arthritis 
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Table 1 gives a brief overview of the salient points of all articles involved in this 
review.  
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A summary of the larger studies from different parts of the world is given below. 
 
The Middle East 
 
There were six studies describing features at presentation arising from countries in the 
Middle East included in this analysis.  Although Egypt is an African country, the 
culture, genetic profile and socioeconomic status is more similar to other countries in 
the Middle East in comparison to Sub-Saharan African countries. 
 
A total of 491 patients were studied in countries in the Middle East.  The male to 
female ratio was 1:4.1.  The commonest presenting features in these patients were 
fever in 69.6% (71/102), musculoskeletal involvement in 61.4% (153/249) and 
haematological involvement in 62% (235/379).  The most reported on features were 
renal involvement, CNS involvement and anaemia.  
 
There were two studies describing the demographic data, presentation and 
clinicolaboratory manifestations of patients with childhood-onset SLE in Egypt.  Salah 
et al studied the largest group in a retrospective folder review of 207 patients.58  Some 
stand out points were a low male to female ratio of 1:2.7 with a relatively low mean 
age of disease onset of 10 years.  Children under five years old made up 4.4% of the 
cohort.  Malar rash (38%) and arthritis (47%) were common presenting features.  The 
kidney was the commonest major organ involved during the course of the disease, 
especially in male patients, but only 21% of patients had renal involvement at 
presentation.  This figure rose to 67% during the course of the disease. 
 
Comparing this study to Bakr’s retrospective study of 52 children, at a dedicated 
Nephrology unit, suggests a different profile.24  With a mean age of onset of 11.9 years 
and 17.3% of patients presenting under the age of ten years old, these were only slight 
differences compared with the difference in the male to female ratio, reported as 1:12 
in this group of patients.  Interestingly, the most common presenting manifestation was 
renal disease (80.8%), closely followed by fever (76.6%) and musculoskeletal 
involvement (65.4%).   
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The second largest study from the Middle East was done in Israel, looking at 102 
patients.60 The male to female ratio was 1:4.4, with a later mean age of diagnosis 
compared to other studies of 13.3 years.  Haematological manifestations were the 
commonest presenting features, present in 94% of patients.  With a relatively low 
amount of renal disease at diagnosis (41%) only a further 12% developed renal disease 
during the course of the illness.  They concluded that with no damage found in 69% of 
their patients, the outcome was good, which could in fact be due to less CNS 
involvement than in other cohorts. 
 
Similar studies looking at the demographic data, clinical features and laboratory 
abnormalities of patients with childhood-onset SLE were conducted in Oman, Iran and 
Kuwait.6,59,61  
 
The Indian Subcontinent 
 
The only study from the Indian subcontinent that met the inclusion criteria looked at 
the profile of paediatric SLE in India, retrospectively reporting on 70 patients.62  Mean 
follow up was 18.8 months, but with a range of 1-96 months, some of the follow up 
was short.  The main features at presentation were fever (94.2%), renal (77.1%) and 
musculoskeletal (65.7%) involvement, as well as a high ESR (98.5%).  The overall 
mortality was 5.7% and renal involvement remained the main cause of morbidity and 
mortality in childhood-onset SLE in India. 
 
The Far East 
 
Two of the largest studies included in this literature review were retrospective studies 
carried out in Taiwan and Thailand.16,63  A total of 254 patients were studied, with a 
male to female ratio of 1:6.0.  The mean age at diagnosis varied between these two 
studies, 13.6 years in Taiwanese patients under the age of eighteen years old at 
presentation compared with 9.7 years in Thailand with an age cut-off of less than 
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fifteen years old at presentation.  The commonest features at presentation were a raised 
ESR in 90.6% (230/254), low C3 in 89% (226/254) and malar rash in 77.1%(118/153).
In 2003, 153 patients from Taiwan were reported on with the main aim of looking at 
the morbidity and mortality of patients with childhood-onset SLE, while also 
discussing the features at presentation.63  Haematological involvement (79.7%), malar 
rash (77%), and renal disease (58.8%) were the commonest clinical presenting 
features.  Only 4.6% of patients had CNS disease at onset.  The study population was 
looked at as a whole, and then analysed in two different cohorts depending on the year 
of diagnosis (1980-1990 v 1991-2001).  There was a significant reduction between 
these two groups in infection, skeletal manifestations and end-stage renal disease 
(ESRD).  Overall mortality was 21.6% at five-year follow-up and 28.8% at ten-year 
follow up.  Being male was actually a good prognostic factor, but having ESRD was a 
poor prognostic factor.  Ten-year survival increased from 44% to 77.5%.  However, 
19% of these patients were lost to follow-up. 
A retrospective folder review of 101 patients in a general paediatric unit in Thailand 
was reported on.16  The aim was to identify presenting symptoms and signs as well as 
laboratory and immunological findings.  The mean age of diagnosis was low at 9.7 
years, with 3% being under the age of five years old and 38.6% being under the age of 
ten years old at diagnosis.  In patients under five years old, the male to female ratio 
was 1:2, compared to 1:5 in five to ten year olds and 1:8 in ten to fifteen year olds.  
Renal disease was present in 86.2% of patients at presentation, with only 31.7% having 
musculoskeletal involvement.  Incidences of cardiac, pulmonary, gastrointestinal and 
musculoskeletal disease were lower, which may be secondary to referral patterns or 
ethnic diversity.  They concluded that age at disease onset, clinical manifestations and 
laboratory investigations are comparable to other reports. 
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North America  
 
356 patients in the studies included in the analysis were from countries in North 
America.  With 17.4% of these patients being male, the male to female ratio was 1:5.7.  
The commonest clinical presenting features in North American studies were cutaneous 
manifestations (79%), musculoskeletal involvement (74.4%), and arthritis (64.4%).  A 
low C3/C4 was present in 76.9% and 87.2% had a raised ESR. 
 
The largest North American study analysed was conducted in Canada aiming to 
determine the frequency and characteristics of clinical symptoms and signs, laboratory 
features and to examine correlations between disease manifestations and disease 
activity over time.65  There was a mean age at diagnosis of 13.1 years with a male to 
female ratio of 1:4.7.  The commonest presenting features were arthritis and malar rash 
(61%).  Renal involvement was present in 37% at disease onset, rising to 55% during 
the course of the disease.  There was a high amount of CNS disease (16%) but most of 
these patients had headaches, which is not part of the ACR diagnostic classification. 
There was a low mortality (2.3%) even with a high incidence of major organ 
involvement. 
 
In Florida in the USA, 39 patients were reported on with one third of these patients 




The South American studies made up 451 of the patients included in the analysis.  The 
commonest clinical features at presentation were constitutional features (100%), 
cutaneous features (80.9%) and arthritis (76.7%).    
 
Of the studies meeting the inclusion criteria, the largest study found was published by 
the GLADEL (Grupo Latino Americano de Estudio de Lupus) group who conducted a 
large multicentre prospective study looking at the clinical characteristics of childhood-
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onset SLE in a cohort of patients with mixed ethnicity.68  A total of 1214 patient of all 
ages with SLE were looked at, with 230 of these patients being under the age of 
eigthteen years old at diagnosis.  There was a mean age of diagnosis of 15.3 years, 
with a mean follow up time of 1.7 years (0.8-2.9 years).  The male to female ratio was 
1:9.  Common presenting features were arthritis (83%), malar rash (70.4%) and fever 
(63.5%).  A large proportion were anti-smith (anti-sm) antibody positive (51.3%) with 
a relatively low amount positive for anti-dsDNA antibodies (67%).  Mortality in this 
group of children was 3.8%.  There was less severe renal impairment in children 
compared with adults, differing from other studies.  They concluded that paediatric 
lupus has a more severe presentation due to higher disease activity indexes, with major 
haematological, cutaneous and CNS involvement. 
 
Retrospective studies were conducted in Chile and Brazil looking at presenting 




Three hundred and thirty-eight patients were included from studies in European 
countries.  In these studies patients generally had fewer features at presentation than in 
other areas of the world.  Only 61.9% of patients had cutaneous involvement with 
48.9% having a malar rash, 15.3% having oral ulcers and 16.9% presenting with 
alopecia.  Of all the areas studied, renal disease was lowest in this group of patients 
(35.8%).  The commonest presenting features in Europe were haematological 
involvement (74.8%) and arthritis (64.5%). 
 
The oldest study included in this review was a multicentre study in the UK looking at 
the clinical and laboratory features in 42 patients.25  Some of the follow up was long 
(mean 7.1 years) with all of the patients being followed-up for at least six months.  
There was a mean age of diagnosis of 13.5 years, with a male to female ratio of 1:7.4.  
All of the patients were ANA positive with a high ESR at diagnosis.  The commonest 
presenting features were musculoskeletal (38%) and cutaneous involvement (21%).   
The mortality was 14.2%, with ESRD, infection and active SLE being the main causes. 
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The largest European study looked retrospectively at the clinical and laboratory 
features at presentation of 155 patients in a multicentre French analysis.69  A 
standardised questionnaire was sent to 89 Paediatric centres in France, with a response 
rate of 73%.  The commonest presenting features were haematological (75%), 
cutaneous (73%) and musculoskeletal (65%) involvement.  In a similar conclusion to 
the study from Florida, one third of the patients had non-classical manifestations of 
SLE at presentation.64  
 
Studies conducted in Spain and the Netherlands reported on smaller cohorts of 




A study of 36 patients in Johannesburg was the only Sub-Saharan study to meet the 
inclusion criteria of this literature review.49  Children under the age of sixteen years 
old were reported on, with the most striking feature being the low male to female ratio 
of 1:2.6.  The commonest presenting manifestations were cutaneous features (77%), 
constitutional features (56%) and renal involvement (44.4%).  They advised of 
warning signs at the end of the study so as to help with earlier diagnosis as many of the 
patients in this population presented with severe disease. 
 
Studies with direct comparisons 
 
The only study included in this analysis directly comparing two different patient 
populations looked at 61 patients from New Orleans in the USA and 110 patients from 
Colombia.66  A cross sectional, comparative, multicentre and binational retrospective 
study based in Rheumatology services was carried out.   
 
They aimed to compare clinical and serological features of SLE in African American 
and Latin American children.  Both groups had a mean age of diagnosis of 13 years 
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old, with the African American children having a higher male to female ratio than the 
Latin American children (1:9.2 v 1:7.5).  The commonest clinical presenting features 
in African American children were cutaneous involvement (84%) and arthritis (79%).  
100% of these patients had a positive ANA and 83% of these patients had 
hypocomplementaemia.  In Latin American children, the commonest clinical 
presenting features were also cutaneous involvement (81%) and arthritis (75%).  
Ninety-six percent had a positive ANA.  More Latin American patients had a low C3 
(86%) and C4 (90%).  African American patients had a higher prevalence of discoid 
lupus and pulmonary fibrosis and a lower prevalence of photosensitivity and livedo 




Only five of the studies included in the review reported on the SLICC/ACR DI as an 
outcome measure for their patients.  Reporting methods varied significantly between 
the studies so it was difficult to do direct comparisons. 
All of these studies were published after 2005 apart from one small European study.  
Three of the five studies had a cohort of more than one hundred patients. 
 
In Canada, 1.7% of patients had disease damage, according to the SLICC/ACR DI, at 
six months after diagnosis.  Overall 34% of all patients in this study scored at least one 
on the SLICC/ACR DI after a mean follow-up time of 3.5 years.  They concluded that 
the majority of patients had major organ involvement in either renal or CNS systems 
and development of involvement in these organ systems was associated with higher 
scores of disease activity at diagnosis as well as a greater frequency of damage.  Aside 
from patients with CNS disease, the nature of disease damage was primarily related to 
medication use rather than the disease process itself.65 
 
The GLADEL group reported briefly on the SLICC/ACR DI scores, saying that the 
maximum score slightly favoured adults with SLE when compared to childhood-onset 
disease.68 
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Mean SLICC/ACR DI scores were reported on in Israel, Brazil and the Netherlands.  
In Israel, 53% of the patients completed at least five years of follow-up.  Their mean 
SLICC/ACR DI score was 0.7 (median 0, range 0-8).  There was a significantly greater 
SLICC/ACR DI score among those patients with renal involvement at diagnosis 
compared to those without initial renal involvement.60  In Brazil, the mean 
SLICC/ACR DI score was 4.9 and SLICC/ACR DI scores did not independently 
influence survival in this study.67  The maximum SLICC/ACR DI score in the 
Netherlands was 12, with a mean of 2.6 and median score of 2.  Muscular atrophy, 
seizures, renal disorders and retinal changes were the main contributors to these scores 
in this group of patients.70 
 
Only three of the areas gave information on renal outcomes – the Middle East, North 
America and South America.  Only 5.3% of the patients (39/736) developed chronic 
kidney disease and 3.7% of the patients (21/565) received dialysis during the study 
periods.60,65,66 
 
The highest amount of patients with chronic kidney disease was in South America, 
occurring in 11.8% of patients, with only 2.5% having chronic kidney disease and 2% 
receiving dialysis in North America.65,66 
 
Overall 12.4% of the patients (92/751) died during the study periods.  This was highest 
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Discussion 
 
The frequencies of the different presenting features in childhood-onset SLE differ from 
country to country and even within the same country.  There are many variables 
hypothesised as to the aetiology of SLE, with genetic, environmental, immunological 
and infective factors all thought to play a role.1  Because of this multifactorial 
aetiology it remains difficult to say whether a specific symptom or sign will occur in 
any individual or any group of patients. 
 
Comparison of presenting features and outcomes is difficult because of differences in 
patient populations.  Each study population is unique.  Patients may be of a different 
race, may have a different severity of disease and be given different treatment 
regimens.  In spite of these limitations some worthwhile observations can be made. 
 
The methods used to collect the data and statistically analyse it varied between studies.  
Retrospective review of medical records was the commonest method, with only a few 
prospective studies meeting the inclusion criteria for this literature review.  In basic 
terms, retrospective studies pose a question and look back, while prospective studies 
ask a question and look forward.  Prospective studies usually have fewer potential 
sources of bias and confounding than retrospective studies.71 
 
Not all of the studies used the same definitions for different organ system involvement.  
A good example of this is the different amount of patients suffering from anaemia as a 
presenting feature of their SLE.  Many of the studies used the ACR diagnostic criteria 
for haemolytic anaemia, while others used an arbitrary cut-off of under 8g/dl or under 
12g/dl as having anaemia at presentation.  With discrepancies like this, one will 
obviously obtain skewed data depending on what definition of ‘anaemia’ was used.  
Other examples of this include hypertension as renal disease and headaches as CNS 
disease, which are not part of the ACR diagnostic criteria for these systems. 
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Age cut-offs for inclusion in the studies reviewed varied, from less than fourteen years 
old in some studies to less than eighteen years old in others.  There is no clear 
definition for the age at which SLE becomes adult-onset disease rather than childhood-
onset disease, and this, along with the fact that different countries have different ages 
at which patients are seen by adult physicians or paediatricians, is the reason for 
varying age cut-offs in the studies.  This obviously gives a wide variation in the age of 
disease onset, male to female ratio and overall presenting features, and means that a 
meta-analysis or direct comparisons are difficult.  Adult-onset disease has been shown 
to present differently to childhood-onset disease, with more renal, CNS and 
haematological involvement in particular being seen in younger patients.8,21,23,72  It has 
been seen that more adult females have SLE than adult males, but it is thought that this 
ratio gets closer together with younger ages of onset.  This can be seen in the studies 
included in the review from South America.  In Chile patients under the age of sixteen 
years old had the lowest mean age at diagnosis (10.6years) with the closest male to 
female ratio (1:3.5) in this area.43  In comparison, in Colombia and Brazil patients 
under seventeen years old had mean ages of onset of 13 years and 12.1 years and male 
to female ratios of 1:7.5 and 1:6.5 respectively.66,67  At the extreme end of South 
American studies, the large multicentre study by the GLADEL group reported on 
under eighteen year olds at disease onset, with a mean age of onset of 15.3 years and a 
male to female ratio of 1:9.68 
The highest male to female ratio (1:18.5) was in North American patients with an age 
cut-off of under eighteen years old.64  On the other hand, the three lowest male to 
female ratios were in studies looking at patients less than seventeen and less than 
sixteen years old.  The lowest male to female ratios were 1:2.4 in the Netherlands, 
1:2.6 in South Africa and 1:2.7 in Egypt.49,58,70  The two studies with a mean age of 
diagnosis under ten years old were both looking at younger patients, with the age cut 
offs being under fourteen years and under fifteen years old.6,16 
In Thailand, the step-wise progression of increasing male to female ratios with 
increasing age was also seen, with a male to female ratio of 1:2 in patients under five 
years old rising to 1:8 in patients between ten and fifteen years old.16  This progression 
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supports some role in sex steroids in the aetiology of SLE, with more females being 
affected the closer to puberty the patients get.  However, sex steroids cannot explain 
how there are a large amount of patients presenting at a young age, some before the 
age of five years old, supporting the idea of multifactorial aetiology. 
 
Although the diagnosis of SLE for inclusion in studies has been defined by the ACR 
criteria, it has to be remembered that SLE is a lifelong disease with changing features 
throughout the course of the disease.19,20  Apart from in one study, all of the patients 
included in the studies analysed met four of the ACR criteria for the diagnosis of SLE 
at time of enrolment.  This one study was included as those not meeting the ACR 
criteria had the diagnosis confirmed through other areas, for example lupus nephritis 
on renal biopsy.69  It is good that a standard has been set for inclusion in studies to 
allow standardisation while carrying out research.  However, it must be remembered 
that patients with SLE who do not meet the ACR criteria but have evolving disease are 
excluded from these studies.  This may mean that patients with milder disease at onset 
and less severe symptoms and organ involvement are excluded from these analyses of 
presenting features. 
 
In the studies anaylsed, although renal involvement and central nervous system 
involvement were the most reported on clinical features at diagnosis, the commonest 
clinical features at presentation were cutaneous, musculoskeletal and haematological 
involvement.   Not surprisingly, as it is the basis of the pathophysiology of the disease, 
96.1% of patients were ANA positive and this was the commonest immunological 
feature in all studies.  On the basis of pathophysiology, it is also not surprising to see a 
high amount of patients with positive anti-dsDNA antibodies, hypocomplementaemia 
and a raised ESR at presentation. 
 
Renal and CNS disease is highly reported on because in many studies these two organ 
systems were classed as major organ involvement if they were involved in the disease 
process.  This is also true for haematological involvement, but this seemed under 
reported on as many of the studies looked at the specific areas within haematological 
disease and did not comment on the total number of patients with haematological 
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involvement at presentation.  Anaemia and thrombocytopenia were actually reported 
on more than the broad category of haematological involvement. 
 
The two largest studies allowing comparison in the same country were from Egypt, 
where different results were given in patients of the same ethnic background.  Both 
studies aimed to describe the demographic, clinical and laboratory features of patients 
with childhood-onset SLE.  Age at onset was similar between the studies.  
Interestingly one patient group was from a Rheumatology setting, while the other was 
from a Nephrology background.  The two initial differences seen were variations in the 
age at diagnosis (10 years v 11.9 years) and male to female ratio (1:2.7 v 1:12).  The 
two major differences in presenting features were the presence of renal disease at 
presentation (21% v 81%) and the presence of anaemia (17% v 51%).  Also, the 
mortality in the two groups differed as well (5% v 15%).  The only other major 
difference between these two studies was in patients who were anti-dsDNA postive 
(66% v 96%).24,58  It is hypothesised that renal disease is a major predictor of poor 
outcome, therefore the higher mortality in patients with more renal disease can be 
expected.24-26  Also anti-dsDNA antibodies are thought to be present in more patients 
with renal involvement.  But the other side of the coin is why are there such huge 
variations in the presenting features in the same country.  These differences are 
through to be due mainly to referral bias but it is impossible to rule out if there is just a 
large variation of disease presentation and disease activity in patients of similar 
ethnicity. 
 
This difference in the sole Nephrology unit raises the issue of possible referral bias.24  
Most of the studies were performed in Rheumatology/Immunology led units or 
multicentre studies.  This can obviously give varying results, as patients with mainly 
one specific organ system involvement may only be seen by their designated sub-
specialty without a great deal of multidisciplinary input.  In all of the studies reviewed 
renal disease was present in 45.9% of patients studied.  As discussed previously, the 
only study from a Nephrology unit had 81% renal involvement at presentation.  The 
highest amount of renal involvement at presentation (86%) was in a study from 
Thailand.16  Two similar studies done in Rheumatology and Autoimmune units gave 
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renal involvement in only 20-21% of patients.23,67  With only 2% having renal disease, 
patients from the UK had the lowest amount, but this was also the earliest study 
included in the review.  It is possible that with improvements in knowledge of the 
disease and investigations, that this number is vastly under representing renal 
involvement – the first patients were recruited in to this study in 1956.25 
 
It is interesting to see how certain features can be almost identical in some ways but 
vary in others between different ethnic groups.  Comparing two groups of patients, one 
from Europe and one from South America, gives the perfect example of this.  With 
similar cutaneous features (73% v 81%), discoid rash (7% v 9%), renal involvement 
(50% v 55%) and musculoskeletal involvement (65% v 75%) you may think that these 
groups of patients had a similar disease profile.  However major differences can be 
seen in other areas, for example CNS disease (17% v 40%), photosensitivity (13% v 
56%) and Raynaud’s phenomenon (10% v 30%).66,69 
 
The only study giving direct comparisons between two different patient populations 
looked at Latin American and African American children.  They concluded that inter-
ethnic differences in the clinical expression of SLE may be explained by the presence 
of genetic, socioeconomic and environmental features, and that this study confirms the 
existence of ethnic differences in clinical and serologic features of SLE in children.66 
 
Although studies from many parts of the world were included in this analysis, this is 
definitely not a worldwide review as many areas of the world were both not 
represented or under represented.  There are no articles reviewed from Australia or 
from Eastern Europe, and only one each from Sub-Saharan Africa and the Indian Sub-
Continent. 
 
South Africa has a vast population mix and has been described as having the highest 
levels of mixed ancestry in the world.  There are however many other areas in the 
world who also have a mixed genetic background.  In particular, both Israel and Latin 
America have diverse multinational and multiracial populations.  In Latin America 
GW Spittal – Characteristics of Childhood-onset SLE in Cape Town, South Africa.  
University of Cape Town February 2014  42
there is significant mixing of races within each country and between countries.  Israel 
is also known to have a unique genetic background by virtue of its mixed ethnicity 
with Jews from various origins and a sizable local non-Jewish population.  Comparing 
presenting features from studies from these areas shows some similarities and some 
differences.  There were similar amounts of renal disease in most of these studies, but 
wide variations in cutaneous involvement, with only 49% of patients in Israel having a 
malar rash compared to up to 70% from the GLADEL cohort in South America.60,68  
CNS involvement was also lower in the Israeli cohort compared with South Africa and 
some Latin American studies.43,49,60,66  It has been hypothesised that these differences 
may be due to socioeconomic and environmental reasons and these comparisons show 
that there are wide variations in disease expression of childhood-onset SLE between 
countries. 
 
Reporting methods of the studies describing SLICC/ACR DI scores varied making it 
difficult to do any direct comparisons.  It can be seen that therapy for the disease 
causes significant morbidity.  This can be seen with cataracts, avascular necrosis and 
muscular atrophy being common indices scored, with these factors being common side 
effects of corticosteroid use.65,70  Renal disease remains a prevalent factor in the 
SLICC/ACR DI scores.  More studies are needed with similar reporting so as to allow 
accurate comparison of results between study groups, and therefore different countries 
and ethnicities. 
 
Mortality varied between countries with some of the studies reporting high mortality 
rates:  e.g. 15% in Egypt, 21.6% and 28.8% in Taiwan and 22% in Brazil.24,63,67  In 
Taiwan, two different cohorts were looked at depending on their year of diagnosis.  
They concluded that ten-year survival probabilities increased significantly from 44.4% 
in the 1980-to-1990 cohort to 77.5% in the 1991-to-2001 cohort.  This indicates a 
decreasing mortality rate.  It has been hypothesised that earlier diagnosis and better 
medical care may contribute to these improvements.  Interestingly, of the four studies 
with the highest mortality rates, three of them were recruiting patients in the 1980’s or 
earlier.25,63,67  The more recent study with a high mortality rate had one of the highest 
number of patients with renal involvement at presentation.  It has been shown that 
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renal disease at presentation can lead to worse outcomes, so maybe this could be 
expected.24  Most of the studies used in the analysis from Europe and North America 
did not report on mortality, so it was difficult to compare rates in developed and 
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Conclusion 
 
The presenting features of childhood-onset SLE vary from country to country and from 
studies from within the same country, with large discrepancies because of age cut-offs 
and subspecialities involved in the studies.  Direct comparisons are difficult because of 
differences in patient populations. 
 
An overview of the current literature has been presented here, highlighting the 
commonest presenting features of childhood-onset SLE i.e. arthritis, malar rash and 
other cutaneous features.  The commonest laboratory features were a positive ANA 
result, a raised ESR and hypocomplementemia. 
 
Direct comparison of outcomes between different countries and different ethnic groups 
was difficult.  In general, survival does seem to be improving over the last twenty 
years.  However, there still needs to be a continued drive to identify which patients are 
more at risk of severe disease, and therefore require more intense therapy, so as to try 
to limit the side effects of the therapy used while minimising damage from the disease 
process. 
 
While there are some common features in most of the studies, there is a wide variation 
of both major and minor organ involvement at presentation. 
 
Although many methodological differences could be cited for the variation in results 
including different ages, different races and different study design, the results do 
suggest that childhood-onset SLE has a wide variation in presenting features. 
 
Further reports with large cohorts are needed to allow further comparisons.  More 
prospective studies would be useful to follow the disease process and to look at factors 
at presentation that may directly affect patient outcomes. 
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Abstract 
 
Objectives:  To describe the presenting features and disease characteristics of 
childhood-onset systemic lupus erythematosus including treatment practices and 
outcomes, looking at those children with renal involvement in greater detail.  
 
Methods:  A retrospective folder review was conducted in children diagnosed with 
systemic lupus erythematosus presenting to the renal or rheumatology services of Red 
Cross War Memorial Hospital and Groote Schuur Hospital in Cape Town, South 
Africa between 1998 and 2009.  Clinical and laboratory manifestations at presentation 
as well as the course of the disease and outcomes were studied.  
 
Results:  Thirty-two children met our inclusion criteria for the study.  The median age 
of presentation was 10 years (range 2.0-14.8 years).  Only four of the patients were 
male, giving a male to female ratio of 1:7. 
 
The most common initial manifestations were renal (59.4%), arthritis (53.1%) and 
malar rash (50%).  Haematological involvement occurred in almost half of the patients 
(46.9%).  Constitutional symptoms were common in particular lymphadenopathy, 
weight loss, fever and lethargy.  Almost 90% of patients presented with involvement 
of either the renal, neurological or haematological systems, or a combination of these 
systems. 
 
Sixty-five percent of patients had a raised erythrocyte sedimentation rate, with 62.5% 
presenting with a low C3 level and 47% presenting with a low C4. 
Antinuclear antibodies, anti-double stranded DNA antibodies, anti-smith antibodies 
and anti-cardiolipin antibodies were positive in 97%, 75%, 31% and 31%, 
respectively.  There was a statistically significant association between having renal 
disease and a positive anti-cardiolipin antibody at presentation (p value = 0.0237). 
 
Nineteen patients presented with renal disease and 17 of these had a renal biopsy.  
Renal disease was more likely to be a presenting feature in younger patients (Risk ratio 
1.93; CI 1.34-2.77).  The majority of patients (59%) had grade IV lupus nephritis.  
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During the course of the follow-up a total of 21 patients had renal involvement.  Seven 
of these required dialysis and five received renal transplantation. 
 
The median Systemic Lupus International Collaborative Clinics/American College of 
Rheumatology damage index score was 1 (range 0-6).  Thirteen patients (42%) had no 
reported long-term damage according to the SLICC/ACR DI. 
 
The overall mortality rate was 6.3%. 
 
Conclusion:  Childhood-onset systemic lupus erythematosus is a complex disease 
presenting in varying ways throughout the world.  In Cape Town, a large proportion of 
patients are presenting with severe disease, most likely presenting late in the disease 
process. In southern Africa, greater awareness is needed of this complex disease and 
its severe initial manifestations. 
 
Keywords 
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Introduction 
Systemic Lupus Erythematosus (SLE) is a multisystem, inflammatory, autoimmune 
disease that is characterised by the formation of antinuclear antibodies.  The aetiology 
remains poorly understood, however environmental, genetic, immunological and 
infective factors are all thought to play a role in the pathogenesis.1 
SLE makes up around 4% of all rheumatological disease and although more commonly 
presenting in adulthood, approximately 15-20% of SLE occurs before the age of 19 
years.1-4   
There is a wide variability in disease presentation and course.  It is known that SLE 
presents differently, not only in respect to age, but also depending on the ethnic 
background and gender of the patient.5-8  The disease appears to be more common in 
Europe, Asia and the Americas than in Africa, but much higher in patients of African 
ancestry living in the United States, United Kingdom (UK) or the Caribbean Islands.9-
11  There is a growing recognition that the perceived low prevalence of lupus in Africa 
is a reflection of under-diagnosis and poor access to healthcare.12  There is a female 
preponderance, but this is also known to vary according to age.4,5,13,14  SLE presenting 
in childhood often involves vital organs and renal disease secondary to SLE can occur.  
This renal involvement contributes significantly to the long-term morbidity and 
mortality in children with SLE.4,15-17
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Paediatric SLE in Africa 
Since SLE was first described in a South African child in 1981, reports of SLE in 
African children have been rare.18-22 There have only been a few case reports from 
Sub-Saharan Africa and one retrospective study looking at childhood-onset SLE in 
South Africa.  In 2005, this study, published from the Gauteng region of South Africa, 
concluded that SLE is being increasingly recognized in black South African children 
and those South African children with SLE present in diverse ways, with the diagnosis 
being missed early.  Therefore patients are presenting late with severe disease.22 
The prevalence of SLE in adult Black South Africans has been estimated to be 
12.2/100,000 although there are no accurate figures available for children in Southern 
Africa.23,24  It has been reported that SLE in indigent adult South Africans carries a 
poor prognosis, with nephritis being common and the only independent predictor of 
poor outcome.23 
South Africa, and Cape Town in particular, has a multi-ethnic population.  Genetic 
studies suggest this group has the highest levels of mixed ancestry in the world, giving 
the Western Cape of South Africa a unique population mix. 25-27    
 
As there is a paucity of data on childhood-onset SLE in South Africa, this retrospective 
study was aimed to describe the disease characteristics at presentation, disease activity, 
treatment practices and outcomes in our cohort of patients with childhood-onset SLE 
from Cape Town, South Africa.  With renal involvement being hypothesised as being a 
major influence on outcome, this study also looks specifically at the patients with renal 
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Methodology 
A folder review of all patients diagnosed with childhood-onset SLE at the Red Cross 
War Memorial Children’s Hospital and Groote Schuur Hospital was performed.  These 
patients were seen in both Rheumatology and Nephrology clinics at these tertiary 
institutes between 1998 and 2009. 
The patient folders were evaluated retrospectively using clinical notes and by review 
of an electronic results database, via the National Health Laboratory Service (NHLS), 
by the two main authors. The notes were cross-evaluated by the second reviewer to 
ensure all appropriate data was collected. 
The following factors were looked at: 
 Demographics – including age, sex and racial background;
 Date of presentation, date of diagnosis of SLE, date of last clinical visit to
hospital;
 Presenting features of the disease – classified according to the American
College of Rheumatology (ACR) Classification Criteria for SLE;28,29
 Other common features at presentation not specifically included in the ACR
criteria;
 Affected systems throughout the course of the disease;
 Any documentation of serious infection requiring hospitalization.
From the above data, age at presentation and length of follow up was calculated. 
The racial/ethnic background was divided in to 3 different categories and classification 
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Laboratory abnormalities at the time of presentation to our referral hospitals were 
recorded including full blood count (FBC), erythrocyte sedimentation rate (ESR), 
serum creatinine levels, complement levels (C3 and C4), urinalysis and serologies 
including titres of antinuclear antibodies (ANA), anti-double-stranded DNA (anti-
dsDNA) antibodies and anticardiolipin antibodies (ACLA).  The glomerular filtration 
rate (GFR) was calculated using the modified Schwartz formula: 
 
     Estimated GFR (eGFR) = (k* x height in cm) / serum creatinine (in mg/dL)30 
[* = k is a  constant that depends on muscle mass, which itself varies with a 
child’s age] 
 
Renal biopsies performed at any time during the course of the illness were reviewed by 
a Consultant Pathologist and were all classified according to the International Society 
of Nephrology/Renal Pathology Society (ISN/RPS) 2003 classification for lupus 
nephritis (LN).31,32 
The Systemic Lupus Erythematosus International Collaborative Clinics/American 
College of Rheumatology damage index (SLICC/ACR DI) was used as an outcome 
parameter for prognosis.33  This was recorded at the time of their most recent visit to 
the hospital.  The specific categories related to scores were recorded. 
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Antibody testing 
Antibody testing was performed by the National Health Laboratory Service of South 
Africa. The following antibody tests were performed using 
Fluoroenzymeimmunoassay on the instrument ImmunoCAP 100 (Phadia, Uppsala, 
Sweden): 
 ANA – EliA Symphony for the in vitro qualitative measurement of antinuclear
IgG antibodies in human serum.  Used together with EliA IgG method;
 Anti-dsDNA antibodies – EliA dsDNA for in vitro qualitative measurement of
IgG antibodies directed to dsDNA in human serum and plasma;
 Anti-smith (anti-Sm) antibodies – EliA Sm for the in vitro quantitative
measurement of IgG antobodies directed to Sm in human serum;
 ACLA – EliA Cardiolipin IgG for the in vitro quantitative measurement of IgG
antibodies directed to cardiolipin in the serum.
Definitions 
Serious infection 
Serious infections were defined as a positive blood culture and/or evidence of raised 
infective markers with admission to hospital requiring at least seven days of 
intravenous antibiotics. 
Ethnicity 
In South Africa, ‘Coloured’ people are an ethnic group of mixed race people who 
possess some sub-Saharan ancestry.  The maternal contribution to the Coloured 
population has been shown to come mostly from the Khoisan population, but it is a 
mixed race possessing ancestry from Europe, Asia and other southern African 
countries.26,27 
Major Organ Involvement At Presentation 
Major organ involvement was defined as the presence of, or combination of, renal, 
neurological or haematological involvement at presentation.  
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Hypertension 
Defined as an average systolic and or diastolic blood pressure that was greater than or 
equal to the 95th percentile for sex, age and height on 3 or more occasions.34 
SLICC/ACR DI score 
The SLICC/ACR DI is the only currently available instrument for measuring disease 
damage in SLE.33 It was recognised that damage from inflammation cannot be clearly 
distinguished from damage secondary to medication side effect’s or other co-morbid 
conditions, therefore both disease specific and non-disease specific damage are 
included in the SLICC/ACR DI.  It quantifies non-reversible cumulative damage, 
which has occurred since the onset of the disease.  It records damage in 12 
organs/systems and has a score range of 0-47. Damage is considered non-reversible if 
any given item was present for at least six months continuously.  It is a validated tool 
for measuring disease damage in adults and children with SLE.35-39 
 
Statistical analysis 
STATA 11.1 was used for statistical analysis.  The Shapiro-Wilks test was used for 
data distribution.  All data was found to be non-parametric.  Expected frequencies 
were calculated and as some frequencies were less than 5, the two-tailed Fisher’s exact 
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Results 
A total of 37 children had a diagnosis of SLE.  Patients with insufficient diagnostic 
features (two or less of the ACR criteria) were excluded.   Patients with only three of 
the ACR criteria were studied in more detail to confirm or refute the diagnosis.  There 
were three patients with fewer than four ACR criteria who were included in the 
analysis: 
 Patient 1 – hepatitis, arthritis, ANA positive and anti-Sm antibody positive –
included due to high specificity of Anti-Sm antibody;
 Patient 2 – class IV lupus nephritis, ANA positive and anti-Sm antibody
positive – included due to confirmed lupus nephritis;
 Patient 3 – cutaneous vasculitis, pulmonary disease, ANA positive, arthritis –
included as patient developed lupus nephritis during the course of follow-up.
The total number of patients included in the study was 32.  All patients had a follow up 
time of at least 6 months, with the average duration of follow up being 5.6 years (range 
0.5 – 17 years). 
There were 4 male patients and 28 female patients giving a male-to-female ratio (M:F) 
of 1:7.  The median age of presentation with the disease was 10 years (range 2.0 – 14.8 
years).  Four of the patients (12.5%) were under 6 years old at presentation, with 12 
patients (37.5%) presenting before their 10th birthday.   
The breakdown of ethnic background is outlined here: 
Figure 1.  Breakdown of ethnic background 
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The commonest clinical presenting feature at presentation was renal disease (59.4%), 
closely followed by arthritis (53.1%) and malar rash (50%).  Constitutional symptoms 
were present in most patients at the time of presentation, with the breakdown of some 
of the more common features shown in table 1. 
   
Table 1.  Clinical presenting manifestations. 
Features Patients (n=32) Percentage (%) 
Female 28 87.5% 
Under 6 years old at presentation 4 12.5% 
Under 10 years old at presentation 12 37.5% 
Renal involvementa 19 59.4% 
Arthritisa 17 53.1% 
Malar rash 16 50% 
Haematological involvementa 15 46.9% 
Central nervous system (CNS) 
involvementa 
2 6.3% 
Photosensitivity 7 21.9% 
Oral ulcers  8 25% 
Serositis 8 25% 
Hypertensionb 7 21.9% 
Lymphadenopathy 11 34.4% 
Loss of weight 10 31.3% 
Lethargy 10 31.3% 
Fever 10 31.3% 
Headaches 6 18.8% 
Raynaud’s phenomenon 4 12.5% 
a   = as per ACR criteria28,29 
b = as per hypertension definition34 
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Twenty-eight of the patients had involvement of the renal, neurological or 
haematological systems, or a combination of the above systems, at presentation.  
Therefore 87.5% of the patients had major organ involvement at presentation. 
The breakdown of laboratory results at presentation is shown in table 2, with a 
comparison made between renal and non-renal patients. 
Table 2.  Laboratory results. 
ANA: antinuclear antibody; Anti-dsDNA: anti-double-stranded DNA; Anti-Sm: anti-smith; ACLA: anti-cardiolipin 





(n = 19)  
NON-RENAL 
PATIENTS (n=13) 
ANA +ve 31 96.9% 19 100% 12 92.3% 
Anti-dsDNA +ve 24 75% 15 78.9% 9 69.2% 
Anti-Sm +ve 10 31.3% 5 26.3% 5 38.4 
ACLA +ve 10 31.3% 9 47.4% 1 7.7% 
False +ve syphilis 0 0% 0 0% 0 0% 
Low C3 20 62.5% 14 73.7% 6 31.6% 
Low C4 15 46.9% 9 47.4% 6 31.6% 
ESR >20 21 65.6% 10 52.6% 11 84.6% 
Hb <10 10 31.3% 6 31.6% 4 30.8% 
Platelets <150 6 18.8% 4 21.2% 2 15.4% 
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Comparisons of presenting features from other studies of childhood-onset SLE from 
around the world are shown in table 3. 



























Cohort 32 36 207 102 101 61 110 230 155 
M:F 1:7 1:2.6 1:2.7 1:4.4 1:6.2 1:9.2 1:7.5 1:9 1:4.5 
Median 
age 
10  10 12
Mean 
age 
10.9 10 13.3 13 13 15.3
Renal 
(%) 
59.4 44.4 21 41 86 44 55 49 50 
Arthritis 
(%) 
53.1 39 47 - - 79 75 83 - 
Malar 
rash (%) 
50 47 38 49 53.5 69 52 70 39 
Haem 
(%) 
46.9 - 45 94 73 - - - 75 
CNS 
(%) 
6.3 19 7 7 21 31 40 - 17
ANA 
(%) 
96.9 - 95 93 96 100 96 97 97 
Haem: haematological; CNS: central nervous system; ANA: antinuclear antibody 
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Table 4 shows the illnesses and systems that were affected throughout the follow up 
but were not present at the time of presentation. 
 
Table 4.  Illnesses and systems affected during follow-up. 
Feature Patients (n=32) Percentage (%) 
Pulmonary Tuberculosis 4 12.5% 
Pleural effusion 5 15.6% 
Pneumonia 4 12.5% 
Other respiratory 5 15.6% 
CNS 10 31.3% 
Cardiovascular 2 6.3% 
Gastrointestinal 5 15.6% 
Musculoskeletal 5 15.6% 
Skin 12 37.5% 
Eyes 5 15.6% 
Haematology 6 18.8% 
Renal 2 6.3% 
CNS: central nervous system. 
 
Twelve of the patients suffered from serious infection during the course of the illness, 
suffering a total of 18 serious infections between them.  Three patients had multiple 
episodes of serious infection. 
 
Renal Patients 
Of the 32 patients with SLE in this study, 19 had confirmed renal disease, as per the 
ACR criteria, at presentation.  Seventeen of these patients (89.5%) had proteinuria of 
more than 0.5g/day and 15 (78.9%) had cellular casts seen on urine at presentation.  
Renal disease was more likely to be a presenting feature in younger patients (Risk ratio 
1.93; CI 1.34-2.77). 
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The eGFR was calculated for all patients presenting with renal disease and these were 
classified using the Kidney Disease Outcome Quality Initiative (KDOQI) classification 
of Chronic Kidney Disease (see table 5):45 
 
Table 5.  Estimated GFR and scoring according to KDOQI classification. 
STAGE GFR DISEASE NUMBER (n=19) % 
1 >89 Kidney damage with normal 
or increased GFR 
6 31.6% 
2 60-89 Kidney damage with mildly 
reduced GFR 
6 31.6% 
3 30-59 Moderately reduced GFR 1 5.3% 
4 15-29 Severe reduction in GFR 1 5.3% 
5 <15 or dialysis Kidney failure 5 26.3% 
GFR: glomerular filtration rate. 
 
Seventeen out of these 19 patients with renal disease had a renal biopsy performed 
during the course of their illness.  The LN was graded accordingly:31,32 
 
Figure 2.  Renal biopsy results 
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Associations were looked at of different presenting features giving an increased risk of 
renal disease at presentation.  There was a statistically significant association between 
having renal disease and a positive ACLA at presentation.  Table 6 shows these 
associations and their respective p values. 
 
TABLE 6.  Associations with renal disease. 
FEATURE AT PRESENTATION P VALUE FOR ASSOCIATION 
WITH RENAL DISEASE 
Age <6 years old vs age >6 years old 0.0641 
Age <10 years old vs age >10 years old 0.7128 
Anti-dsDNA positive vs anti-dsDNA negative 0.6838 
ACLA positive vs ACLA negative 0.0237 
Anti-Sm positive vs anti-Sm negative 0.6993 
Low C3 or C4 vs normal C3 and C4 0.4181 
ESR  >20 vs ESR <20 0.229 
Anti-dsDNA: anti-double-stranded DNA; ACLA: anticardiolipin antibody; Anti-Sm: anti-smith; C3: complement 
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Treatment  
The disease modifying treatment given at any time during the course of the illness is 
shown in table 7. 
 
Table 7.  Treatment given during course of illness. 
DRUG NUMBER (n=32) PERCENTAGE (%) 
Oral corticosteroid 32 100% 
Azathioprine 21 65.6% 
Chloroquine 21 65.6% 
Mycophenolate mofetil 12 37.5% 
Methotrexate 10 31.3% 
Cyclophosphamide 14 43.8% 
Intravenous Immunoglobulin 3 9.4% 
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Outcome 
The breakdown of the SLICC/ACR DI scores is as follows (one patient had inadequate 
clinical notes to do an accurate score): 
 
Figure 3.  Breakdown of SLICC/ACR DI scores. 
 
The median SLICC/ACR DI score after follow-up was 1, ranging from 0 to 6.  
Thirteen patients (42%) had no reported long-term damage according to the 
SLICC/ACR DI.  
Renal involvement was the commonest system to be scored in the SLICC/ACR DI (6 
patients), followed by pulmonary (4 patients) and musculoskeletal (4 patients) 
involvement. 
 
Dialysis and transplant 
During the course of their follow up in this study, a total of 21 patients had renal 
involvement - two patients developed it during the course of the disease.  Of these, 
seven required dialysis and five received renal transplantation. 
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Mortality 
Two patients died, giving an overall mortality of 6.3%.   One patient died in 2006 due 
to end stage renal disease (ESRD) while the other died more recently in 2010 from 
extensively drug-resistant tuberculosis. 
GW Spittal – Characteristics of Childhood-onset SLE in Cape Town, South Africa.  
University of Cape Town February 2014  71
Discussion 
The objective of this study was to determine the clinical presentation, treatment 
practices and outcomes of childhood-onset SLE in a South African population that has 
never before been reported on.  
Despite the many published cases of childhood-onset SLE, its true incidence and 
prevalence is unknown.  One of the main reasons for this is that there is not a strict 
definition of childhood-onset SLE.  The most frequent cut-off ages are 14 or 16 years 
old at onset of the disease.  However, several studies use a higher or lower cut-off age.  
In our study we used a cut off of 16 years because over this age patients are referred to 
the adult services in our area. 
Comparison of outcomes with other studies is difficult because of differences in 
patient populations.  Each study population is unique.  Patients may be of a different 
race, may have a different severity of disease and be given different treatment regimes.  
In spite of this limitation, certain comparisons have been made in this study. 
 
Ethnicity 
There are numerous different racial backgrounds in our study population, defined as 
Black African, White and Coloured.  Genetic studies suggest that our cohort has one of 
the highest levels of mixed ancestry in the world, giving the Western Cape of South 
Africa a unique population mix.25-27  There have been many reports from all over the 
world, but with most of the patients in this study group being from the Coloured 
population, this study population is of unique ethnicity which has never before been 
reported on.  
 
Male to female ratio with age 
In childhood-onset disease, a progression of increasing male to female ratios occurring 
with increasing age has been reported.14  Our study also showed this progression, with 
a male to female ratio of 1:3 for six to ten year old children and 1:9 for children 
presenting after their tenth birthday.  
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Our overall male to female ratio was 1:7.  Some other studies from Africa have shown 
a much lower male to female ratio; 1:2.6 in South Africa and 1:2.7 in Egypt.22,40  
However in North America (1:18.5) and Europe (1:10), as well as in another study 
from Egypt (1:12), higher ratios, similar to that seen in adults, have been 
reported.15,46,47   
Our patients had a median age of 10 years, which was similar to a much larger study 
from Thailand, which also had a median age of 10 years and a similar male to female 
ratio of 1:6.2.14  However, around the world the age at onset and female preponderance 
in childhood-onset SLE varies considerably.   
 
Major organ involvement at presentation 
Major organ involvement at presentation has been reported to be a major influencing 
factor on the long-term prognosis of patients with childhood-onset SLE.3,16,48  Almost 
90% of our patients presented with major organ involvement, agreeing with the 
previous view that children, unlike adults, commonly present with major organ 
involvement.4,47,49,50   
The fact that most of our patients presented with major organ involvement at 
presentation supports the conclusion from Faller et al that patients in South Africa 
present late with severe disease at presentation.22  Despite this our patients had 
relatively good outcomes in terms of SLICC/ACR DI scores and mortality.  The 
correlation of major organ involvement at presentation and poor outcome was not 
shown in this cohort of modest size.  It must be remembered, however, that mild cases 
may not be included in this analysis as they may remain unreported due to them not 
being referred to the tertiary institute for further evaluation. 
 
Different presenting features and comparison 
There is a wide variation among different studies in the prevalence of manifestations 
of childhood-onset SLE.  This may be due to differences in the genetic make up of 
patients who come from various ethnic backgrounds, age at presentation, or from 
referral bias.  The most frequent findings in this population at presentation were renal 
involvement, arthritis, malar rash and haematological involvement.   Renal disease was 
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also the highest prevalent factor in another South African study, although at lower 
levels (44%).22  Also, up to 58% of their patients had developed renal disease by the 
end of the their follow up time, compared to 66% of our patients.  On the other hand, 
they reported much higher CNS involvement at presentation (6.3 vs 19%), which is 
similar to that reported in France and Thailand.14,44 Our relatively lower incidence of 
CNS involvement is similar to Northern African areas as well as other areas of mixed 
ethnicity.15,40,41,51  There were hugely varying reporting of haematological involvement 
at presentation, ranging from 45% in Egypt and 47% in our study, to as high as 94% in 
Israel.40,41 One possible explanation for this is the specific definition used for 
haematological involvement, although the Israeli study also used the ACR diagnostic 
criteria for haematological involvement.41 
With renal involvement, arthritis and malar rash being the commonest presenting 
features, this is similar to Colombian children.42  However, they had a much higher 
amount of photosensitivity and Raynaud’s than our patients.  The fact that this was a 
retrospective study means that these features, most often illicited in history, may not 
have been consistently well documented. 
Although the presenting features of childhood-onset SLE in our diverse population 
group was similar to other countries throughout the world, some key differences can be 
seen, and no common thread can be clearly identified.  
 
Laboratory results 
Most large series of childhood-onset SLE included a variable number of patients with 
SLE who were ANA negative at presentation, usually 3-5%.40,43,44,52  This can also be 
seen in our patients, where all bar one were ANA positive at time of presentation. 
Anti-dsDNA antibodies have been reported to be positive in 85-95% of patients, but 
this is lower in our study (75%).  One reason could be improving laboratory techniques 
to diagnose this autoantibody positivity.  In this small cohort of African children, 
ACLA positivity at presentation was helpful as a diagnostic aid associated with the 
presence of renal involvement.   
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The presence of anti-Sm antibodies is a very specific, but not sensitive test for the 
diagnosis of SLE.53  In our study, we found only 31% of patients with anti-Sm 




It has been shown that patients with SLE have a greater susceptibility to infections and 
that this is a leading cause of mortality in this group of patients.16,56-58  The increased 
frequency of serious infection observed in this study most probably results from the 
combined effect of the disease itself and the use of immunosuppressive therapy. 
Although 37.5% of our patients had a serious infection at some point during their 
follow up, only one of the patients died from an infective cause.  In our patient 
population there is a high prevalence of TB and it can be seen that 12.5% of our 
patients developed TB during the follow-up period.  This is an added complication to 
deciding treatment regimens, ensuring we maximise treatment while limiting 
immunosuppression and other potentially serious side effects. 
 
Renal Patients 
Lupus nephritis (LN) is considered to be more frequent and more severe in children 
than adults.4  The incidence of LN in the present study was 59.4%, which is 
comparable to another study carried out in a mixed Nephrology/Rheumatology unit.59  
However, it is lower than some other African countries as well as in Thailand, but 
much higher than the reported 20-21% in another Egpytian study, as well as in Europe 
and South America.14,15,40,47,51  Hypotheses for these differences could be referral bias 
and the different specialties looking after the patients.  There seemed to be varying 
incidences of renal involvement depending on whether the studies were conducted in 
Nephrology, Rheumatology, or mixed Nephrology/Rheumatology units.  
There was an increased risk of developing LN with younger age at onset and, with 
renal disease being a major factor in morbidity and mortality, this supports the 
hypothesis of childhood-onset disease in South Africa presenting late in the disease 
process, especially in patients under the age of 6 years old.   
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Biopsies.  As we used the newer ISN/RPS classification for renal biopsies in LN, there 
were limited direct comparisons to make between our study and other, larger reports.  
However, it can easily be seen that this study confirms the severity of the initial renal 
disease in childhood-onset SLE patients, with class IV LN occurring in over 50% of 
those biopsied.  This high incidence of Class IV disease is similar to many studies 
throughout the world.60-63  Class IV LN is defined as diffuse LN in both the newer 
ISN/RPS classification as well as the older WHO classification of LN.31,32,64,65 
 
Chronic Kidney Disease.  Our patients with renal disease seemed to fall in to 2 main 
categories.  Using the KDOQI classification of Chronic Kidney Disease, the majority 
(63.2%) had mild kidney damage or kidney damage with normal renal function.  On 
the other hand, just over a quarter of patients (26.3%) had kidney failure at 
presentation.   
ESRD has been reported to be 10% in African Americans and 12% in Latin 
Americans.42  These values are obviously lower than our reported 26.3% of patients 
having ESRD, supporting the hypothesis of our cohort of patients presenting with 
more severe disease than in other areas throughout the world. 
 
Pharmacological treatment 
The management of SLE and LN is very difficult.  As there is no single aetiology, 
there is no single cure to the disease. The aim of therapy at all stages of childhood-
onset SLE is to maximise the therapeutic effect while minimising disease activity and 
adverse effects.   
The European League Against Rheumatism (EULAR) recommendations for the 
management of SLE support using antimalarials with or without glucoroticoids in the 
treatment of all patients with SLE, even without major organ involvement.66  Although 
the use of corticosteroids remains the first line treatment, it is essential that every effort 
be made to minimise their dosage because of the extensive adverse effect profile.  The 
early use of chemotherapeutic/cytotoxic agents and the development of newer, more 
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selective medications is aiming to improve control of the disease process while 
limiting adverse effects caused by the medication. 
Corticosteroid therapy was used universally in our patients with childhood-onset SLE.  
This was supported by anti-malarials and further immunosuppressive therapy in the 
majority of patients.   Historically not all patients were started on Chloroquine but in 
recent years this has been prescribed to all patients in line with international evidence 
based guidelines. 
 
As most of our patients presented with major organ involvement, the use of further 
immunosuppressive agents in these patients is warranted, in particular in patients with 
lupus nephritis, where they have been shown to be effective against the progression to 
ESRD.66-71  Long-term efficacy has been demonstrated for cyclophosphamide based 
regimens, but this has been associated with considerable adverse effects.72,73  
Mycophenolate Mofetil (MMF) is an alternative treatment that was used in almost a 
third of this cohort.  In recent trials, MMF has demonstrated similar efficacy, 
especially in patients with moderate to severe forms of lupus nephritis, with a more 
favourable toxicity profile.74-79  
Only a few patients were treated with intravenous immunoglobulin therapy.  
Rituximab was used for one patient with Thrombotic Thrombocytopenic Purpura and 
severe renal disease.  
 
Outcome 
Outcome was assessed using three parameters:  the SLICC/ACR DI, progression to 
ESRD and survival. 
 
SLICC/ACR DI Scores.  Reporting methods in many studies using the SLICC/ACR 
DI scores varied making it difficult to do any direct comparisons with our studies.  
However, is can be seen that other studies reported significant morbidity due to the 
therapy for the disease, as well as the disease process itself.  This can be seen with 
cataracts, avascular necrosis (AVN) and muscular atrophy, mainly as side effects to 
prolonged corticosteroid use, being common indices scored.7,37,54,55  In our patients we 
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saw limited scores for the complications related to therapy, and most of our patients 
had scores related to the disease process, with renal disease being a prevalent factor in 
the SLICC/ACR DI scores. This could be related to short follow up time, the relatively 
young age of patients, as well as a therapeutic approach aimed at reducing 
corticosteroid exposure. 
 Despite many of our patients presenting with major organ involvement results of the 
SLICC/ACR DI were similar to other worldwide studies.   With 58% of our patients 
having a SLICC/ACR DI score of one or more, indicating some degree of damage, this 
is comparable to other larger studies.7,37,54,80,81   However a large, multicentre world-
wide study had only 50.5% having some degree of damage.38  Some of these studies 
have reported higher median SLICC/ACR DI scores of 2 compared with our median 
score of 1.37,55,80  These studies have involved larger cohorts of patients, but with 
similar follow-up times.  A larger study in Israel, where there is also a mixed ethnic 
population, showed better results, with 69% of their patients having no damage, with a 
mean SLICC/ACR DI score of 0.7 and a median score of 0.41  Better comparisons 
could be made if more patients were recruited in to our study.  However, all of our 
patients were deemed unwell enough to be referred to our tertiary unit, maybe 
indicating that they are at the more extreme end of the disease spectrum, which can be 
supported by the high amount of major organ involvement at presentation.  
It must also be remembered that although the SLICC/ACR DI has been validated for 
use in childhood-onset SLE, it does not cover all forms of damage that children or 
adolescents with SLE may develop over time, particularly effects on growth and 
development.  It has been suggested that growth retardation and pubertal delay should 
be included in a paediatric version of the SLICC/ACR DI.37 
Dialysis and Transplant.  The Red Cross War Memorial Children’s Hospital is a 
referral unit for a large area of Southern Africa and we offer dialysis and transplant 
services.  Although SLE was once regarded as a contraindication to transplantation, 
dialysis and renal transplantation are currently regarded as the treatment of choice for 
ESRD in childhood-onset SLE patients.66,67  Long-term patient and graft survival has 
been good in patients with SLE, and transplantation is the method of choice.82-84  A 
third of patients with renal involvement received dialysis for their kidney failure and 
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most of these patients (71%) received renal transplantation during the course of the 
illness.  One of the patients who received dialysis died due to ESRD.  All of the 
patients who received a kidney transplant are still alive, with all bar one of the patients 
having no further sequelae of the disease or the treatment of the disease according to 
the SLICC/ACR DI. 
In Egypt, 5.3% of patients received renal dialysis, 5% of those from Israel and 2% of 
those from Canada.40,41,54  These numbers were all much lower than our 21.9% of 
patients, again indicating that our patients had more severe disease, especially in renal 
involvement.  
In Egypt, it has been reported that 1.4% of their patients with renal disease received a 
renal transplantation.40  This is much lower than our 23.8% of renal patients who went 
on to receive a renal transplantation.  The fact that we have access to transplantation 
could explain why there is a better outcome amongst our patients, with renal 
transplantation being shown to be successful in children with SLE.82 
 
Mortality.  In the last thirty years the prognosis of SLE presenting in childhood has 
improved dramatically.  There is a bimodal pattern of mortality, either from initial 
disease activity or from complications relating to either the disease itself or from 
therapies used in the treatment of the disease.85  In the early 1980’s, survival at 5 years 
from onset in childhood-onset SLE was reported to be between 89-92% in Western 
countries.86-88 However, in developing nations, survival was much poorer, reported as 
low as 68% and 55.7% in Chile and Japan.89,90  This has improved to 95% and 95.9% 
in these nations respectively.   
With the majority of our patients being followed up for more than 3 years (66%), our 
mortality rate in this small study of only 6.3% is comparable to studies from other 
developing nations, for example between 5% and 6% in Egypt, India and Chile.40,90,91  
This is despite a large proportion of patients presenting with major organ involvement 
and a relatively high proportion of patients presenting with renal involvement, two 
factors that have been associated with poorer outcome.15-17,48,90  
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Limitations 
This study was limited in its analysis by the low patient numbers and the fact that it 
was a retrospective study. Larger patient numbers looked at in a prospective fashion 
are needed for more complete analysis of clinical manifestations and laboratory results.  
This would also allow trends and comparisons to be made with more confidence as 
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Conclusion 
This is a unique population group never before studied.  Although the presenting 
features of childhood-onset SLE in our diverse population group were similar to other 
countries throughout the world, some key differences can be seen and no common 
thread can be clearly identified.  Differences in the clinical expression of SLE in 
different populations may be explained by the presence of genetic, socioeconomic and 
environmental factors.   
The age at onset, clinical manifestations and laboratory result at presentation of 
childhood-onset SLE in Cape Town were comparable to other reports from around the 
world, although each group of patients seems have subtle differences from the rest.  
SLE is a diverse disease, affecting many different organs of the body and it looks like 
no two groups of patients are identical in disease profile. 
A large proportion of our patients presented with major organ involvement, agreeing 
with another South African study that our patients are most likely presenting later in 
the disease process.  Renal disease was more likely in our younger patients and 
urinalysis of patient with suspected SLE is vital.  Patients with positive anticardiolipin 
antibodies must also be closely screened for renal involvement. 
Despite a lower age of onset and a high proportion of patients with major organ 
involvement at presentation the outcome and mortality in these patients was generally 
good.  Earlier diagnosis, better treatment protocols and aggressive management of both 
lupus nephritis and infections have all contributed to the improved outcome in this 
severe disease. 
More studies looking at childhood-onset SLE in Southern Africa should lead to a 
greater awareness of this complex disease and its severe initial manifestations.  
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Appendix 1.  Data collection sheet. 
Study number Race Gender      m / f 
DOB    /    / Date First Presentation: Date Diagnosis SLE:   Date Last Seen: Duration Follow up 
Clinical Data 
Height (centile): 1st     last:    Weight: 1st    last:   Features at presentation Malar Rash Discoid Rash Photosensitivity Oral Ulcers Arthritis (2 or more joints) Serositis : Pleuritis          pericarditis Renal Disorder: Persistent Proteinuria ( 3+or >0.5g/day)        Cellular Casts Neurologic Disorder: Seizures (absence of other cause)        Psychosis (absence of other cause) Hematologic Disorder: Hemolytic Anemia with reticulocytosis              Leukopenia  (<4000/mm3) X2 occasions        Lymphopenia ( <15000/ mm3  ) X2 occassions Immunologic Disorder: Positive Anti ds-DNA   Positive  anti SM nuclear antigen          False Positive for syphyllis Antinuclear Antibody: Hep2          Elisa Other manifestations not included above: CNS    M/S CVS    Skin Resp   Eyes GIT    Haem Renal     Fever Reynauds    Lymphadenopathy Weight loss 
Affected Systems throughout course (also state final outcome per system) 
CNS          M/S CVS           Skin Resp         Eyes GIT        Haem Renal  (see detailed box below) 
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Serious Infections(requiring IV antibiotics or admission or prolonged treatment(>1week) 
No of Infections during course of follow up: Positive Cultures Organsisms: 
Renal Disease Blood: Prot:  Prot/Creat:  24hr protein  Ceatinine/GFR:  
1st 1yr 5yr Last
Biopsy: GradeDialysys/transplant:   Date: 
C3/C4 1st 1yr 5yr Last ESR 1st 1yr 5yr Last
ANA: Method: 1st  1yr 5yr Last Anti ds DNA 1st 1yr 5yr last
AntiCardiolipin LAC 1st Last: Hb:WCC Plt 1st 1yr 5yr last SLEDAI 1st 1yr 5yr last SLICC 1st 1 yr 5yr Last
Treatment Steroids Azathioprine MMF Chloroquine  Methotrexate Cyclophosphamide (Cumulative Dose) Polygam (Cumulative Doses) Rituximab (Cumulative Dose) Other 
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Total Time on Therapy(days) Steroids AZA MMF Chloroquine MTX  Comments and Outcome Sustained remission: Ongoing periods of active disease: Deceased: Cause of death: 
Additional Comments 
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Appendix 2.  1997 Update of the 1982 American College of Rheumatology revised 
criteria for classification of systemic lupus erythematosus. 
1. Malar Rash Fixed erythema, flat or raised, over the malar eminences, tending to 
spare the nasolabial folds 
2. Discoid rash Erythematous raised patches with adherent keratotic scaling and 
follicular plugging; atrophic scarring may occur in older lesions 
3. Photosensitivity Skin rash as a result of unusual reaction to sunlight, by patient 
history or physician observation 




Involving 2 or more peripheral joints, characterized by tenderness, 
swelling, or effusion 
6. Pleuritis or
pericarditis
1. Pleuritis--convincing history of pleuritic pain or rubbing
heard by a physician or evidence of pleural effusion OR
2. Pericarditis--documented by electrocardigram or rub or
evidence of pericardial effusion
7. Renal disorder 1. Persistent proteinuria > 0.5 grams per day or > than 3+ if
quantitation not performed  OR




1. Seizures--in the absence of offending drugs or known
metabolic derangements; e.g., uremia, ketoacidosis, or
electrolyte imbalance  OR
2. Psychosis--in the absence of offending drugs or known




1. Hemolytic anemia--with reticulocytosis  OR
2. Leukopenia--< 4,000/mm3 on ≥ 2 occasions  OR
3. Lyphopenia--< 1,500/ mm3 on ≥ 2 occasions  OR




1. Anti-DNA: antibody to native DNA in abnormal titer OR
2. Anti-Sm: presence of antibody to Sm nuclear antigen  OR
3. Positive finding of antiphospholipid antibodies on:
1. an abnormal serum level of IgG or IgM
anticardiolipin antibodies,
2. a positive test result for lupus anticoagulant using a
standard method, or
3. a false-positive test result for at least 6 months
confirmed by Treponema pallidum immobilization
or fluorescent treponemal antibody absorption test
11. Positive
antinuclear antibody
An abnormal titer of antinuclear antibody by immunofluorescence 
or an equivalent assay at any point in time and in the absence of 
drugs 
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Appendix 3.  Systemic Lupus International Collaborating Clinics/American College 
of Rheumatology Damage Index for systemic lupus erythematosus.* 
Item Score 
Ocular (either eye) Any cataract ever 1 
Retinal change or optic atrophy 1 
Neuropsychiatric Cognitive impairment or major psychosis 1 
Seizures requiring therapy for 6 months 1 
Cerebrovascular accident ever (score 2 if >1) 1 (2) 
Cranial or peripheral neuropathy (excluding optic) 1 
Transverse myelitis 1 
Renal Estimated or measured glomerular filtration rate <50% 1 
Proteinuria ≥3.5gm/24hours OR 
End-stage renal disease (regardless of dialysis or transplant) 
1 
3 
Pulmonary Pulmonary hypertension (right ventricular prominence, or loud P2) 1 
Pulmonary fibrosis (physical and radiograph) 1 
Shrinking lung (radiograph) 1 
Pleural fibrosis (radiograph) 1 
Pulmonary infarction (radiograph) 1 
Cardiovascular Angina or coronary artery bypass 1 
Myocardial infarction ever (score 2 if >1) 1 (2) 
Cardiomyopathy (ventricular dysfunction) 1 
Valvular disease (diastolic murmur, or systolic murmur >3/6) 1 
Pericarditis for 6 months, or pericardiectomy 1 
Peripheral Vascular Claudication for 6 months 1 
Minor tissue loss (pulp space) 1 
Significant tissue loss ever (e.g. loss of digit or limb) (score 2 if >1) 1 (2) 
Venous thrombosis with swelling, ulceration or venous stasis 1 
Gastrointestinal Infarction or resection of bowel below duodenum, spleen, liver or gallbladder 
ever, for any cause (score 2 if >1 site) 
1 (2) 
Mesenteric insufficiency 1 
Chronic peritonitis 1 
Stricture or upper gastrointestinal surgery ever 1 
Musculoskeletal Muscle atrophy or weakness 1 
Avascular necrosis (AVN) (score 2 if >1) 1 (2) 
Osteoporosis with fracture or vertebral collapse (excl AVN) 1 
Deforming or erosive arthritis (incl reducible deformities, excl AVN) 1 
Osteomyelitis 1
Skin Scarring chronic alopecia 1 
Extensive scarring or panniculum other than scalp and pulp space 1 
Skin ulceration (excluding thrombosis) for >6 months 1 
Other Premature gonadal failure 1 
Diabetes (regardless of treatment) 1 
Malignancy (excluding dysplasia) (score 2 if >1 site) 1 (2) 
* Damage (non reversible change, not related to active inflammation) occurring since the onset oflupus, ascertained by clinical assessment and present for at least 6 months unless otherwisestated.  Repeat episodes must occur 6 months apart to have score 2.  The same lesion cannot bescored twice.
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Appendix 4.  Ethics approval and annual progress report/renewal. 
UNlVERSrfY OF CJ,. PE TOWN , 
12 February 2010 
REC REF: 073/2010 
DrC Scon 
Paediatrics 
Dca,- Dr Scott 
Hea1th Scieoces Faculty 
Research Ethics Committee 
Room E52-24 Grootc Schuur Hospital Ok! Main Building 
Obscrvatory 7925 
Tclephone [021J 406 6626 • Facs imile (021]406 6411 
e-mail: shuretlll.t:homas@ueue.u 
PROJECT TITLE: CHARACTERISTICS OF CHILDHOOD SYSTEMIC LUPUS 
ERYI'HEMATOSUS IN CAPE TOWN, SmITH AFRICA. 
Thank you for submitting your study 10 the Rescatcll Ethics Committtt. 
It is a pleasure 10 inform you that the Ethics Committee has fo rmally approved the above-mentioned srudy 
including the following documenllltion. 
Approval is gnmled fot O DC year riU the l{)lt> December 2010. 
Please submit an annual progress ttpon if the rucarch continues beyond the apiry date. Please lubmit a brief 
swnmaIf of findings if you complete the study within the approval period so that we can close our file. 
Please note that a form to uodert:ake re5ean::h al Red Cross Children's Hospit:al is available on the HREC's 
website. 
Please note that the ongoing ethieal conduct of the study remains the responsibility of the principal 
investigator. 
Please qUOle thc REC. REF in all your correspoDdcnce. 
Yours sinttrdr 
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UNIVERSITY Of CAPE TOWN ." " ." , •. " ... , .... ,.,.." ... FACULTY OF HEALTH SCIENCES 
"'"man R_rth Ethics Committee 
FHS017: Annual Progress Report I Renewal 
Record Reviews/Audits/Collection of Bioloalcal SDecimenslReoosltoriesiOatabasesiR i5me , 
HREC office use only (FWA00001637: 1I~.800001938) 
This res .. notification of annu.1 approval. ineludlng any doeument.tion deseribed below. 
11"'_ Annual progress report I Approved until/next renewal date !l:,lrLl"o/3 
o Not approved See attached comments / 
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I Department / OffICe P.I\cw\1<I\C flf4lf", "" KeJ Gw, UtM'I.<9J.l ~'J i Internal Mail Address l" 
1,.1 Does lhia protoc:ol reeeive US Federal funding? 10 Yes ,_, 
2. Protocol s tatus /tick ""i 
o Research-related activities are ongoing 
IT" Data c:oIection II complete. data analyall only 
3 . Protocol summary 
Total number d records Of specinens collected, reviewed Of stored since the original 
apuoval n· 
Total number of reoords or specimens collected. reviewed or stored since last progress J1-report 
Have any research-f8lated outputs (e.g. publlQltJons. abstracts, conference DYes "-"",, 
presentatio!"1s1 resulted from this researeh? If ytlli. please li't and attach with 
th is report 
4 . Signature ~. ~Ucrt 
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Appendix 5.  SAGE manuscript submission guidelines for Lupus journal. 
 
The only fully peer reviewed international journal devoted exclusively to lupus (and 
related disease) research. Lupus includes the most promising new clinical and 
laboratory-based studies from leading specialists in all lupus-related disciplines. 
  
1. Peer review policy 
The journal's policy is to obtain at least two independent reviews of each article. Lupus 
operates a conventional single-blind reviewing policy in which the reviewer's name is 
always concealed from the submitting author. 
Referees will be encouraged to provide substantive, constructive reviews that provide 
suggestions for improving the work and distinguish between mandatory and non-
mandatory recommendations. 
All manuscripts accepted for publication are subject to editing for presentation, style 
and grammar. Any major redrafting is agreed with the author but the Editor's decision 
on the text is final. 
  
2. Article types 
Lupus is published fourteen times a year. The Editor will consider for publication all 
suitable papers dealing directly or indirectly with lupus or related diseases. The journal 
includes both clinical and non-clinical research papers. In addition to peer-reviewed 
(two referees) original papers, the journal also publishes editorials, reports, and letters. 
 
EDITORIALS 
Editorials are solicited by the Editor but suggestions for such material will be very 
welcome. 
 
GRAND ROUNDS CASES 
The purpose of a grand rounds submission is to educate the reader about one or more 
facets related to the disease lupus or of an autoimmune disease which is related to 
lupus. A clinicopathological conference can be submitted but this must have 
postmortem data and is usually a death conference or mortality conference. 
Avoid extraneous material which has little bearing on the case at hand. The readers 
wish to learn about every facet of the case presented and not about other unrelated 
material. 
The submitted case should contain: 
Introduction - This should be no more than one or two short paragraphs and summarise 
what is about to be presented and the reasons why the case was chosen. 
Case Presentation - This part contains a succinct narrative of the case itself. Figures, 
photographs and tables with data are welcome. Also encouraged are data on biopsies 
with illustrative materials if possible. 
Discussion - The discussion should be a focused presentation of theory and/or 
pathogenetic data regarding the case. 
Final Diagnosis - This should be only one sentence which gives the final diagnosis. 
 
CONCISE REPORTS 
These should be short investigative papers and reports organised in the same way as 
full-length manuscripts but which contain 2000 words or less, with no more than 3 
figures or tables and up to 15 references. 
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CASE REPORTS 
The Editor will consider for publication case reports that illustrate points not 
previously reported in the literature. They should not exceed two printed pages in 
length. The number of references should not exceed ten. 
The number of case reports published will be strictly limited. 
 
LETTERS TO THE EDITOR 
Letters to the Editor are encouraged. They may deal with material in published papers 
or they may raise new issues. Short clinical or laboratory observations may also be 
presented as Letters. 
Letters must contain no more than 500 words, 10 references, 1 table and/or 1 
illustration. An abstract is not required and letters should not be divided into sections. 
Instructions for references, tables and figures are the same as for full length articles. 
 
SUPPLEMENTS 
The journal welcomes the opportunity of publishing supplements to regular issues of 
significant symposia providing the material represents original work not previously 
published. 
Sponsored symposia should be fully discussed with the Editor prior to agreement to 
publish. 
Faculty, subject matter and editorial content are all subject to the approval of the 
editorial office and the journal's integrity and reputation should in no way be 
compromised. 
  
3. How to submit your manuscript 
Before submitting your manuscript, please ensure you carefully read and adhere to all 
the guidelines and instructions to authors provided below. Manuscripts not conforming 
to these guidelines may be returned. 
  
4. Journal contributor’s publishing agreement     
Before publication SAGE requires the author as the rights holder to sign a Journal 
Contributor’s Publishing Agreement.  
Lupus and SAGE take issues of copyright infringement, plagiarism or other breaches 
of best practice in publication very seriously. We seek to protect the rights of our 
authors and we always investigate claims of plagiarism or misuse of articles published 
in the journal. Equally, we seek to protect the reputation of the journal against 
malpractice. Submitted articles may be checked using duplication-checking software. 
Where an article is found to have plagiarised other work or included third-party 
copyright material without permission or with insufficient acknowledgement, or where 
authorship of the article is contested, we reserve the right to take action including, but 
not limited to: publishing an erratum or corrigendum (correction); retracting the article 
(removing it from the journal); taking up the matter with the head of department or 
dean of the authors institution and/or relevant academic bodies or societies; banning 
the author from publication in the journal or all SAGE journals, or appropriate legal 
action. 
 
4.1 SAGE Choice 
If you wish your article to be freely available online immediately upon publication (as 
some funding bodies now require), you can opt for it to be included in SAGE Choice 
subject to payment of a publication fee. The manuscript submission and peer 
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reviewing procedure is unchanged. On acceptance of your article, you will be asked to 
let SAGE know directly if you are choosing SAGE Choice. 
  
5. Declaration of conflicting interests                    
Within your Journal Contributors Publishing Agreement you will be required to make 
a certification with respect to a declaration of conflicting interests. It is the policy 
of Lupus to require a declaration of conflicting interests from all authors enabling a 
statement to be carried within the paginated pages of all published articles. 
Please include any declaration at the end of your manuscript after any 
acknowledgements and prior to the references, under a heading ‘Conflict of Interest 
Statement’. If no declaration is made, the following will be printed under this heading 
in your article: ‘None Declared’. Alternatively, you may wish to state that ‘The 
Author(s) declare(s) that there is no conflict of interest’. 
When making a declaration, the disclosure information must be specific and include 
any financial relationship that all authors of the article have with any sponsoring 
organization and the for-profit interests that the organisation represents, and with any 
for-profit product discussed or implied in the text of the article. 
Any commercial or financial involvements that might represent an appearance of a 
conflict of interest need to be additionally disclosed in the covering letter 
accompanying your article to assist the Editor in evaluating whether sufficient 
disclosure has been made within the Conflict of Interest statement provided in the 
article. 
  
6. Other conventions 
 
6.1 Informed consent 
Authors are required to ensure that the following guidelines are followed, as 
recommended by the International Committee of Medical Journal Editors. 
  
Patients have a right to privacy that should not be infringed without informed consent. 
Identifying information, including patients' names, initials, or hospital numbers, should 
not be published in written descriptions, photographs, and pedigrees unless the 
information is essential for scientific purposes and the patient (or parent or guardian) 
gives written informed consent for publication. Informed consent for this purpose 
requires that a patient who is identifiable be shown the manuscript to be published.  
Complete anonymity is difficult to achieve, however, and informed consent should be 
obtained if there is any doubt. For example, masking the eye region in photographs of 
patients is inadequate protection of anonymity. If identifying characteristics are altered 
to protect anonymity, such as in genetic pedigrees, authors should provide assurance 
that alterations do not distort scientific meaning and editors should so note. 
When informed consent has been obtained it should be indicated in the submitted 
article. 
Authors should identify individuals who provide writing/administrative assistance, 
indicate the extent of assistance and disclose the funding source for this assistance.  
Identifying details should be omitted if they are not essential. 
 
6.2 Ethics 
When reporting experiments on human subjects, indicate whether the procedures 
followed were in accordance with the ethical standards of the responsible committee 
on human experimentation (institutional or regional) or with the Declaration of 
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Helsinki 1975, revised Hong Kong 1989. Do not use patients' names, initials or 
hospital numbers, especially in illustrative material. When reporting experiments on 




Any acknowledgements should appear first at the end of your article prior to your 
Declaration of Conflicting Interests (if applicable), any notes and your References. 
All contributors who do not meet the criteria for authorship should be listed in an 
‘Acknowledgements’ section. Examples of those who might be acknowledged include 
a person who provided purely technical help, writing assistance, or a department chair 
who provided only general support. Authors should disclose whether they had any 
writing assistance and identify the entity that paid for this assistance. 
 
7.1 Funding Acknowledgement 
To comply with the guidance for Research Funders, Authors and Publishers issued by 
the Research Information Network (RIN), Lupus additionally requires all Authors to 
acknowledge their funding in a consistent fashion under a separate heading. 
  
8. Permissions 
Authors are responsible for obtaining permission from copyright holders for 
reproducing any illustrations, tables, figures or lengthy quotations previously 
published elsewhere. 
  
9. Manuscript style 
Authors are asked to write their manuscripts in English. Spelling and phraseology 
should conform either to standard UK English or to standard American English and 
should be consistent throughout the paper. 
The Summary should not exceed 200 words. It should be written in a style that 
conveys the essential message of the paper in abbreviated form. 
The Introduction should assume that the reader is knowledgeable in the field and 
should therefore be as brief as possible. 
In the Materials and methods section, methods that have been published in detail 
elsewhere should not be described in detail. SI units should be used throughout the 
text. 
 
9.1 File types 
Only electronic files conforming to the journal's guidelines will be accepted. Preferred 
formats for the text and tables of your manuscript are Word DOC, and tiff or jpeg for 
figures (ideally figures will use journal colours).  
 
9.2 Journal Style 
Lupus conforms to the SAGE house style. 
 
9.3 Reference Style 
Lupus adheres to the SAGE Vancouver reference style.  
 It is important that references comply with the style of the journal. Exhaustive lists 
should be avoided. References should follow the Vancouver format, listed (double-
spaced) in numerical order corresponding to the order of citation in the text. 
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All authors should be quoted for papers with up to six authors; for papers with more 
than six authors, the first three only should be quoted followed by et al. 
No issue numbers should be quoted. 
Abbreviations for titles of medical periodicals should conform to those used in the 
latest editions of Index Medicus and Current Contents. The first and last page numbers 
for each reference should be provided. Abstracts and letters must be identified as such. 
Papers in press and papers already submitted for publication may be included in the list 
of references. No citation is required for work that is not yet submitted for publication. 
Personal communications may be allocated a number and included in the list of 
references in the usual way or simply referred to in the text. Authors must obtain 
permission from the individual concerned to quote his or her unpublished work. 
Examples of References: 
 
Journal article: 
1 Derksen RHWM, Bouma BN, Kater L. The association between the lupus 
anticoagulant and cerebral infarction in systemic lupus erythematosus. Scand J 
Rheumatol 1986; 15: 179-184. 
 
Journal article, in press: 
2 Mendonca LLF, Khamashta MA, Nelson-Piercy A, Hunt BJ, Hughes GRV. 
Nonsteroidal anti-inflammatory drugs as a possible cause for reversible infertility. 
Rheumatology (in press). 
 
Journal article submitted for publication: 
3 Khamashta MA, Cervera R, Asherson RA. Association of antibodies against 




4 Wallace DJ, Dubois EL. Dubois' Lupus Erythematosus. Lea & Febiger, 1987, p 51. 
 
Chapter in book: 
5 Christian CL. Etiologic hypotheses for systemic lupus erythematosus. In: Lahita RG 
(ed) Systemic Lupus Erythematosus. Wiley, 1987, 65-79. 
 
Abstract: 
6 Valesini G, Luan FL, Falco M. Clonal analysis of affinity purified anticardiolipin 
antibodies. Clin Exp Rheumatol 1988; 6: 214 (abstract 102). 
 
Letter to the Editor: 
7 Sills EM. Systemic lupus erythematosus in a patient diagnosed as having Shulman 
disease. Arthritis Rheum 1988; 31: 694 (letter). 
 
9.4. Manuscript Preparation 
The text should be double-spaced throughout and with a minimum of 3cm for left and 
right hand margins and 5cm at head and foot. Text should be standard 10 or 12 point. 
SI units should be used throughout the text. 
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9.4.1 Keywords and Abstracts 
The title, keywords and abstract are key to ensuring that readers find your article 
online through online search engines such as Google.  
 
9.4.2 Corresponding Author Contact details 
Provide full contact details for the corresponding author including email, mailing 
address and telephone numbers. Academic affiliations are required for all co-authors. 
 
9.4.3 Guidelines for submitting artwork, figures and other graphics 
 
TABLES 
Each table should be numbered consecutively with an Arabic numeral. Each should 
have a separate caption or title. Methods not described in the text and abbreviations 
should be explained at the foot of the table. Footnotes should be designated by superior 
lower case letters (a, b, c etc). Vertical lines should not be inserted in the table. Tables 
must be referred to specifically in the text of the paper. 
 
FIGURES 
Lettering should be planned for 50% reduction; text should be readable after reduction. 
Figures should be referred to as Figure 1, Figure 2 etc. Figures must be referred to 
specifically in the text of the paper. 
Images should be supplied as bitmap based files (i.e. with .tiff or .jpeg extension) with 
a resolution of at least 300 dpi (dots per inch). Line art should be supplied as vector-
based, separate .eps files (not as .tiff files, and not only inserted in the Word or pdf 
file), with a resolution of 600 dpi. Images should be clear, in focus, free of pixilation 
and not too light or dark. 
Colour photographs and Figures - Important information: 
Colour photographs and Figures, when accepted, will be published online. In the 
printed version, they will be in black and white (unless colour prints are paid for). 
Authors who submit in colour must ensure that their figures are of the highest 
definition for the black and white version otherwise these may not be accepted. In 
particular immuno-fluorescent and histological figures, as well as skin rashes, must be 
paid for in colour or omitted from the manuscript and replaced in a descriptive format. 
If, together with your accepted article, you submit usable colour figures, these figures 
will appear in colour online regardless of whether or not these illustrations are 
reproduced in colour in the printed version. For specifically requested colour 
reproduction in print, you will receive information regarding the possible costs from 
SAGE after receipt of your accepted article. 
 
9.4.4 Guidelines for submitting supplemental files  
The journal may be able to host approved supplemental materials online, alongside the 
full-text of articles. Supplemental files will be subjected to peer-review alongside the 
article.  
 
9.4.5 English Language Editing 
Non-English speaking authors who would like to refine their use of language in their 
manuscripts should have their manuscript reviewed by colleagues with experience of 
preparing manuscripts in English. 
Alternatively it might be useful to consider using a professional editing service.  
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